

Inflammageing, a targetable pathway for preventing cardiovascular diseases

Juan Francisco Aranda¹, Cristina M. Ramírez ^{2*}, and María Mittelbrunn^{3*}

¹Department of Genetics, Physiology and Microbiology, Faculty of Biology, Complutense University of Madrid, C. de José Antonio Novais, 12, 28040 Madrid, Spain; ²IMDEA Research Institute of Food and Health Sciences, Carretera de Cantoblanco number 8, 28049 Madrid, Spain; and ³Tissue and Organ Homeostasis Program, Centro de Biología Molecular Severo Ochoa (CBM), Consejo Superior de Investigaciones Científicas (CSIC)—Universidad Autónoma de Madrid (UAM), Calle Nicolás Cabrera 1, 28049 Madrid, Spain

Received 20 March 2024; revised 3 July 2024; accepted 23 July 2024; online publish-ahead-of-print 12 November 2024

Inflammageing, characterized by persistent chronic inflammation in older adults, has emerged as a critical factor linked to age-related diseases, such as cardiovascular diseases (CVDs), metabolic disorders, and cognitive decline, which collectively contribute to the leading causes of death globally. Elevated levels of cytokines, chemokines, and other inflammatory mediators characterize inflammageing and serve as indicators of biological age. Among the causes of inflammageing, deterioration of the immune system, mitochondrial dysfunction, dysbiosis, accumulation of DAMPs, together with genetic or epigenetic factors, contribute to inflammageing not only in CVD but also in other age-related conditions. This review examines the causes and consequences of inflammageing, particularly its implications for atherosclerosis and heart failure with preserved ejection fraction and explores potential strategies to mitigate it in the onset of CVD.

Keywords Inflammation • Atherosclerosis • Heart failure • HFpEF • Ageing

This article is part of the Spotlight Issue on Ageing.

1. Introduction

Ageing is defined as the gradual and inevitable process characterized by a progressive decline in functional capacity and heightened susceptibility to diseases, culminating in frailty—a clinical syndrome marked by diminished physiological reserves and increased vulnerability to adverse health outcomes in older adults.^{1,2} The complexity of ageing, encompassing factors such as genetic, epigenetic, cellular, and environmental influences, underscores the absence of a definitive cure for ageing. While certain interventions, such as caloric restriction and pharmacological agents, have shown promise in delaying age-related diseases in model organisms, their efficacy and safety in humans are yet to be fully understood.³ Inflammageing is the persistent chronic inflammation that emerges during ageing and has been coupled with age-related conditions, such as cardiovascular diseases (CVDs), metabolic disorders, non-alcoholic fatty liver disease, chronic kidney disease, and cognitive decline.⁴ Altogether, these diseases represent the leading causes of death worldwide. Understanding the causes and consequences of inflammageing and its relationship with age-associated diseases is, therefore, a priority for public health, especially now that the global population is ageing. Inflammageing is now considered a hallmark of ageing¹ because it meets the three criteria: (i) the gradual appearance of changes that occur accompanying the ageing process, (ii) the ability to speed up ageing through experimental intensification of the identified

characteristic, and (iii) the potential to slow down, stop, or even reverse ageing through therapeutic interventions targeting the identified hallmark. Furthermore, studies have demonstrated the hallmarks of ageing, including inflammageing, across species, are evolutionary conserved as well as the underlying pathways and mechanisms of this phenomenon, which will be elaborated later on.^{5,6}

The circulating concentration of inflammatory mediators, such as cytokines and chemokines, and biomarkers of inflammation, such as C-reactive protein (CRP), increase with age. In fact, biological age can be estimated by measuring inflammatory mediators in the blood.⁷ This inflammatory clock of ageing has been called iAge and tracked with multimorbidity, immunosenescence, frailty, and cardiovascular ageing. One of the contributors to iAge is the CXCL9 chemokine, which has been involved in vascular ageing and adverse cardiac remodelling. Among the other cytokines and chemokines that are elevated with ageing, tumour necrosis factor alpha (TNF- α) and interleukin-6 (IL-6) stand out.⁸ In fact, high levels of IL-6 are predictive biomarkers of all-cause mortality in ageing human populations. A substantial subset of older individuals shows inflammasome activation leading to caspase-1-mediated maturation of proinflammatory cytokines, such as IL-1 β and IL-18.⁹ Lastly, the proinflammatory chemokine CCL5 has also been shown to be increased in the bone marrow of aged animals, promoting neutrophil accumulation and bone loss.^{10,11} As such, anti-inflammatory agents, lifestyle interventions such as exercise and

* Corresponding authors. Tel: +34911964528, E-mail: mmittelbrunn@cbm.csic.es (M.M.); Tel: +34 917278100 (312); fax: +34 91 188 07 56, E-mail: cristina.ramirez@imdea.org (C.M.R.)

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.




Figure 1 Causes of inflammaging. The presence of PAMPs due to physical rupture of intestinal barrier or persistent chronic infections activate inflammatory pathways in the IS. In addition, cells undergoing stress release DAMPs like mtDNA, formylpeptides, and ROS, and some of them become senescent with the characteristic SASP-secreting inflammatory signals. Of note, release of DAMPs, PAMPs, and SASPs contribute to inflammaging and foster the deterioration of the IS affecting to quality and quantity of immune responses and worsening inflammaging. These factors, together with intrinsic factors that contribute to the deterioration of the IS, like CHIP, myeloid skewing, high NLR, thymus involution, and antigen exposure. PAMPs, pathogen-associated molecular patterns; DAMPs, damage-associated molecular patterns; mtDNA, mitochondrial DNA; ROS, reactive oxygen species; CHIP, clonal haematopoiesis of indeterminate potential; NLR, neutrophil to lymphocyte ratio; SASP, secretory-associated senescence phenotype.

nutrition, and pharmacological treatments targeting specific inflammatory pathways are among the potential approaches to improve the condition of frail older adults.^{2,12}

In this review, we will discuss the current knowledge about the causes of inflammaging and its consequences for CVDs, with a special focus on potential strategies to control inflammaging that could be employed to delay the onset of CVDs.¹³

1.1 Causes behind inflammaging

The causes of inflammaging are complex and involve various factors that contribute to persistent chronic inflammation during ageing. The main feature of inflammaging is that it occurs in the absence of evident aggression to the organism and at the same time, it prevents the effective and specific response to antigen stimulations. Some key factors related to the appearance of inflammaging include immune system (IS) deterioration, the secretory-associated senescence phenotype (SASP) due to accumulated senescent cells, and accumulation of DAMPs driven by a breakdown in mitochondrial endosymbiosis and microbial commensalism or by persistent infections (Figure 1, Table 1). Additionally, some of the molecular mechanisms and signatures of inflammaging share strong similarities between mouse and human species in terms of immune/inflammatory response, suggesting that it is evolutionarily conserved and, more importantly, that the results obtained in mouse trials could be easily translated to future therapies in humans.⁴⁷

2. Changes in the IS

During ageing, there is a deterioration of IS function. This phenomenon, known as immunosenescence, results in a dysregulated immune function that instead of mounting specific immune responses, engages useless inflammatory responses.

As the ageing process unfolds, intricate alterations manifest in both the adaptive and innate branches of the IS, marked by a reduction in circulating lymphocytes (T and B cells) and an elevation in myeloid cells (mostly neutrophils). This imbalance of immune populations culminates in an increased

neutrophil-to-lymphocyte ratio (NLR) in the organismal circulation. A high NLR predicts mortality and poor prognosis in virtually all age-associated diseases as well as during natural ageing. The heightened infiltration of neutrophils into tissues induces damage¹⁷ and triggers tissue senescence¹⁸ during the ageing process and inflammation. The decrease in the frequency of both CD4 and CD8 T cells in circulation is accompanied by significant alterations in the subsets of T lymphocytes. This comprehends a reduction in the naïve pool and an increase in effector/memory T cells with a terminally differentiated phenotype.⁴⁸ Effector memory T cells (TEM), exhibiting exhausted, cytotoxic, and senescent features, lose the capacity to migrate to lymph nodes and spleen, acquiring instead the ability to migrate to non-immune tissues. This shift in T-cell population from naïve towards terminally differentiated phenotype compromises immunosurveillance, increases autoimmune diseases, and reduces the repair of biological barriers, altogether fostering inflammaging.⁴⁹ Age-associated alteration studies in immune cells led to the identification in mouse organs of a subpopulation of granzyme K (GZMK)-expressing CD8⁺ T (Taa) distinct from TEM. Interestingly, humans share the proportion of this circulating GZMK⁺ CD8⁺ T-cell subset and the transcriptional and epigenetic signature with mouse T cells during ageing, suggesting that inflammaging is a conserved process across species and therefore represents an attractive therapeutic target.⁵⁰

As it is observed in numerous other cell types throughout the body, T cells exhibit a decline in mitochondrial function as they age. Although this failure may be originated primarily in mitochondria, other intracellular compartment defects, such as lysosome and autophagosome, can affect T-cell activation, which in turn lead to an exacerbated and/or incorrect immune response and the loss of homeostasis. Defects in lysosomal acidification through cytokine-inducible SH2-containing protein expression in CD4⁺ T cells promote release of mitochondrial DNA (mtDNA), which increases inflammatory serum cytokines and reduces antibody production.⁵¹ In fact, mitochondrial insufficiency triggers the functional exhaustion terminal state of T cells through the oxidative stress-HIF-1 α (hypoxia inducible factor 1)—metabolic reprogramming pathway.⁵² Therefore, targeting mitochondrial and lysosomal dysfunction in T-cell responses may offer a potential approach to mitigate inflammation and enhance immune function in the ageing population.

Table 1 Sources of inflammaging, description, and molecular targets involved

Source	Description	Molecular targets	Refs.
NLRP3 inflammasome activation	Involved in inflammaging and HFpEF pathogenesis	NLRP3, Caspase-1 cleavage, NF- κ B, chemokines (CCL5)	14–16
Immunosenescence	Malfunctioning of IS, unadaptive, or insufficient response	CDXX, KLRG1, TEM, CHIP, myeloid skewing, thymus involution	17–21
Proinflammatory Cytokines	Elevated levels linked to inflammaging and mortality in ageing populations	IL-1 β , IL-6, TNF- α	22,23
DAMPs and SASP	Accumulation contributes to chronic inflammation and inflammaging	mtDNAs, succinate, fumarate, N-formyl peptides, AGEs, ROS, Cardiolipin, and ATP	24–28
Mitochondria	Dysfunction plays a role in inflammation and cellular ageing	Mutations in mtDNA, ROS, TCA, OXPHOX, PGC-1 α , and TFAM	29–38
Genetic/epigenetic factors	Influence inflammaging through gene expression and epigenetic modifications	MiRNAs (CHIP: DNMT3A, TET2, ASXL1), SNPs, DNA methylation, and histone modifications	25,39–43
Intestinal microbiota PAMPs	Dysbiosis impacts systemic inflammation and ageing processes	Calprotectin, LPS, TCA metabolites	44–46

We and others have previously contributed to demonstrate that the deterioration on the IS function with ageing is sufficient to induce organismal ageing and age-related multimorbidity.^{19,20} Data from our lab show that T-cell-specific mitochondrial defect by depleting the mitochondrial transcription factor A (TFAM) not only mimics age-associated T-cell mitochondrial dysfunction and recapitulate the main hallmarks of T-cell ageing, but is also sufficient to drive cardiovascular, cognitive, metabolic, and physical ageing coupled to premature inflammaging. The TNF inhibitor etanercept delays this phenotype. These results support that ageing of T cells may drive inflammaging and organismal ageing. In fact, haploinsufficiency of the DNA repair protein ERCC1 in haematopoietic cells is also sufficient to induce senescence of non-lymphoid organs, as well as numerous signs of organ damage coupled to reduced lifespan.⁵³

Recently, a new subset of CD4 T lymphocytes with a cytotoxic phenotype characterized by the expression of the EOMES transcription factor producing granzymes and CCL5 has been reported that appears during ageing and is especially abundant in supercentenarians.¹⁴ The results from our lab support that this subset infiltrates the bone marrow during ageing, favouring myeloid skewing and the overproduction of neutrophils.¹⁰

Most of the changes in immune population frequencies and phenotypes predominantly result from:

- (1) *Alterations in bone marrow, myeloid skewing, and clonal haematopoiesis of indeterminate potential (CHIP; Figure 2)*. Distinct factors contribute to increased levels of neutrophils during ageing, but the most recognized cause is a skewing of haematopoiesis towards the differentiation of myeloid progenitors at the expense of lymphoid progenitors.⁵² CHIP is a common age-related condition characterized by the clonal expansion of haematopoietic stem cells bearing mutations in certain genes, especially DNMT3A, TET2, and ASXL1.^{39,40} These mutations affect myeloid cells, such as macrophages and neutrophils, leading to increased expression of inflammatory genes, which might account for the increased risk of cardiovascular complications in individuals with CHIP. In fact, TET2-deficient macrophages showed increased IL-6 production and NLRP3 inflammasome activity reflected in IL-1 β secretion.²² Moreover, CHIP driven by TET2 also favours CVD, which is attenuated by treatment with canakinumab, an anti-IL-1 β antibody.²³ Similarly, monocytes of heart failure (HF) patients harbouring DNMT3A driver mutations exhibited markedly increased expression of inflammatory genes, including NLRP3 inflammasome.^{15,16}
- (2) *Thymus involution*. The thymus is the primary immune organ responsible for generating self-tolerant and immunocompetent T cells. However, the thymus gradually involutes during early life resulting in declined naive T-cell production. Thymic involution has many negative impacts on immune function, including reduced pathogen resistance, high autoimmunity incidence, and attenuated tumour immunosurveillance contributing to inflammaging.^{21,54}

- (3) *History of antigen recognition*. As we encounter antigens and pathogens over time, the cumulative effect on our IS can accelerate immunosenescence, potentially leading to increased susceptibility to infections and decreased ability to mount robust immune responses.⁵⁵ Altogether, these alterations in immune cellular subsets and function contribute to inflammaging.

3. Accumulation of senescent cells in tissues

As cells undergo the process of ageing, they may transition into a state of senescence, wherein they halt their division yet maintain metabolic activity. Senescent cells exhibit arrested cellular cycle, resistance to apoptosis, and are characterized by an SASP.²⁴ The accumulation of senescent cells producing elevated amounts of proinflammatory cytokines and SASP cell extrinsic factors favours inflammaging driving the decline in immunological protection as we age, thereby targeting these cells might be a strategy to delay inflammaging. A very recent study has found conserved epigenetic clocks in memory T cells both in murine and in human species, as shown by DNA methylation profiles of replicative senescence-associated genes in this cell population.²⁵ Although the IS is prepared to recognize and eliminate senescent cells in a physiological way, the age-associated deterioration of the IS or the expression of immunosuppressive ligands, such as PD-L1 and PD-L2 by senescence cells could favour the accumulation of senescence cells in the tissues.²⁶

Senolytics are a class of drugs and natural products that deplete senescence cells through apoptosis. In a preclinical trial with middle-aged non-human primates, 6 months of intermittent treatment with a senolytic combination of dasatinib and quercetin delayed inflammaging probably via immune benefits and improved intestinal barrier function.⁵⁶ Same senolytics also prevent mtDNA induced inflammaging in older organs.⁵⁷ In addition, other compounds named senomorphics inhibit senescence-associated secretory phenotype by targeting pathways related to SASP expression, such as the p38MAPK, PI3k/Akt, mTOR, and JAK/STAT pathways and transcription factors, such as nuclear factor kappa B (NF- κ B), C/EBP- β , and STAT3, therefore reducing systemic inflammation. Metformin is an example of senomorphic with anti-inflammaging properties⁵⁸ and therapeutic potential as a treatment for CVD.⁵⁹

4. Mitochondrial dysfunction and break in mitochondrial endosymbiosis

With ageing, the function of mitochondria declines due to multiple inter-laced mechanisms including the accumulation of mtDNA mutations and




Figure 2 Molecular mechanisms of inflammaging. In the heart and the vasculature, inflammaging promotes oxidative stress and increases inflammatory mediators such as CRP and adhesion molecules that result in ECM and lipidome remodelling. Additional factors, such as epigenetic changes, including oscillations in levels of several miRNAs, has been shown to contribute to the sustained inflammation that lead to endothelial dysfunction, atherosclerosis, vascular injury, and heart failure. CVD, cardiovascular disease; HFpEF, heart failure preserved ejection fraction; CRP, C-reactive protein; ECM, extracellular matrix; PUFA, polyunsaturated fatty acids; miRNA, microRNA; IL-1, interleukin-1; IL-6, interleukin-6; TNF, tumour necrosis factor.

deletions, reduced turnover of the organelle, and changes in mitochondrial dynamics. The deterioration in mitochondria function not only compromises the cellular bioenergetics state, but also can contribute to inflammaging. Mitochondria constitute a latent trigger of inflammation due to their endosymbiotic origin.²⁹ Mitochondria retain many bacterial remnants that can act as damage-associated molecular patterns (DAMPs). Under stress conditions, mitochondrion-derived molecules, such as mtDNAs, succinate, fumarate, *N*-formyl peptides, reactive oxygen species (ROS), cardiolipin, and ATP, are released from mitochondria and activate several inflammatory pathways.^{30–32} MtDNA present in many copies within mitochondria is not methylated at CpG and is more susceptible to oxidative damage due to its location and its limited repair capability. The mtDNA release to the cytosol can trigger a cascade of inflammatory innate responses, such as cGAS stimulator of interferon (IFN) gene expression, Toll-like receptor 9 (TLR9) pathway activation, and cytosolic inflammasome formation.³³ Circulating mtDNA appears to increase gradually with age after the fifth decade of life, and the abundance of unhoused mtDNA is associated with accelerated ageing.³⁴ The 13 polypeptides translated within mitochondria are all initiated with an *N*-formyl methionine. These mitochondrial proteins, including *N*-formyl peptides, primarily induce inflammation through binding to formyl peptide receptor-1.³⁵ On the other hand, after the formation of double-strand breaks in the mtDNA, herniation mediated by BAX and BAK releases mitochondrial RNA (mtRNA) into the cytoplasm stimulating NF- κ B through RIG-I and mitochondrial antiviral-signalling protein. Consequently, this leads to activation of Type I IFN response.³⁶

In addition to mtDNA, mtRNA, formyl peptides, and ROS, mitochondrial dysfunction releases tricarboxylic acid cycle (TCA) intermediate metabolites into the cytosol with inflammatory effects³⁷ such as fumarate or succinate. Fumarate inhibits lysine-specific demethylase 5 A (KDM5) histone demethylase activity and inhibition of KDM5 increases the levels of H3K4me3, a marker

of active gene transcription at the promoters of TNF- α and IL-6 cytokine.³⁸ Furthermore, elevated levels of succinate, resulting from mitochondrial dysfunction, may contribute to chronic inflammation by activating the HIF-1 α pathway through stabilization of the hypoxic transcription factor HIF-1 α . Succinate inhibits prolyl hydroxylases, enzymes responsible for the degradation of HIF-1 α thus stabilizing HIF-1 α that translocates into the nucleus and initiates the transcription of inflammatory cytokines, such as IL-1 β .⁶⁰

5. Dysbiosis, intestinal barrier dysfunction, and leaky gut

The integrity of the intestinal barrier is essential for the health of the organism throughout life. Intestinal barrier dysfunction is an evolutionarily conserved feature of aged organisms, as it has been reported in worms, flies, fish, rodents, and primates.⁶¹ Pioneers studies come from the drosophila model using a non-absorbable blue food approach to monitor intestinal barrier function in living flies.^{62–64} In these assays, the presence of the dye outside of the digestive tract throughout the body is an indicator of intestinal barrier dysfunction which is called Smurf phenotype. By separating Smurf flies by chronological age, the authors showed that intestinal barrier dysfunction is a better predictor of mortality than chronological age. Moreover, this study also reported that intestinal barrier dysfunction was associated with additional markers of health decline, including markers of inflammaging.⁶³ The disrupted intestinal barrier is the cause of changes in microbiota composition, known as a gut dysbiosis and can also be affected by the deterioration of the IS.⁴⁴ Changes in permeability allow some bacteria and their molecules, PAMPs, to enter the circulatory system enhancing inflammaging. Faecal calprotectin is a general marker of gut

inflammation that consist in a heterodimer of S100 calcium-binding proteins that is primarily expressed in immune cells and can be released from the cytosol of activated neutrophils. Recent studies have shown that levels of faecal calprotectin are associated with advanced age and Alzheimer's disease⁴⁵ and with acute HF.⁶⁵ The lipopolysaccharide (LPS)-binding protein, which is known as a marker of clinical endotoxaemia, and the soluble form of CD14 (sCD14), co-receptor for LPS, are both also used as markers of gut permeability and bacterial translocation.⁴⁶

6. Accumulation of DAMPs

As state before, the age-related rupture of both mitochondrial endosymbiosis and intestinal barrier constitutes an immense source of DAMPs and PAMPs. Additionally, even though the human body is provided of complex and well-regulated mechanisms to repair or eliminate degraded cellular material, during age-associated diseases, there is an accumulation over time of diverse biological debris.²⁷ These metabolites also include advanced glycation endproducts (AGEs), oxLDL, high mobility group protein B1, ATP, and many others. Our IS recognize them and is activated constantly due to inability to be eliminated by other mechanisms. Ultimately, the sustained activation of innate and adaptive immunity branches by DAMPs triggers the hyper-responsiveness of myeloid and lymphoid cells contributing to chronic inflammation.²⁸

6.1 Genetic predisposition, chronic infections, endocrine changes, and environmental factors

Other causes that contribute to heterogeneity of inflammageing are related to each individual and include genetic predisposition, chronic infections, endocrine changes, and environmental factors. Over the past decades, studies with human populations demonstrated the link of genetic variants with the proinflammatory profile found in the blood biomarkers.⁶⁶ The most relevant genetic associations are those related to SNP, such as IL1RN minor alleles, multiple SNP in CRP gene or in the promoter region of IL-6.^{41–43} However, a large divergence has been observed during ageing in the inflammatory markers in twins for many of these genetic variants, suggesting that the influence of environmental factors is also remarkable. In many other cases, there are strong evidence that inflammageing is powered by the relative abundance of micro RNAs (miRNAs) in circulating cells or plasma during ageing as we will explain latter in this review.⁶⁷ The response of the IS to some persistent infections may become dysregulated with age, such as cytomegalovirus (CMV) and HIV or bacterial infections. The reactivation episodes against these viruses can contribute to chronic inflammation over time, but the mechanism behind this is still unclear. One hypothesis in the case of human-persistent CMV infection is that it accelerates immunosenescence of memory T-cell compartment in older individuals. In fact, a new population of CD57⁺CD28⁻CD8⁺ T cells, which are enriched in individuals with HIV and CMV chronic infections, are associated with immunosenescence, suggesting a link to chronic viral infections and immune dysregulation.⁶⁸ Ageing is associated also with physiological changes in the endocrine system. Hormone levels can impact the IS and contribute to maintain an inflammatory state due to excessive or deregulated trophic signals resulting in activation of GH/IGF1/Pi3K/AKT/mTORC1 signalling pathways.⁶⁹ For example, adiponectin and leptin are affected in adipocytes in several fat depots during obesity and ageing, and together with the circulating proinflammatory signals of chemokines/cytokines foster inflammageing. A recent study using a mouse model has linked the altered nutrient sensing through mTOR signalling with senescence and myeloid inflammation and neutrophil infiltration in tissues reducing lifespan.⁷⁰ Sex hormones, specifically androgens and oestrogens, can modulate inflammatory responses. Whereas oestrogens can exhibit either anti-inflammatory (at high concentrations) or proinflammatory (at low concentrations) effect, androgens shown anti-inflammatory effects both *in vivo* and *in vitro*.⁷¹ Accordingly, sex/gender differences in inflammageing are shown during immune ageing when sex hormones decline. While older women have higher adaptive immune activity, older men show higher activity for

monocytes and inflammation, indicating greater inflammageing in men.^{72–74} Moreover, the X chromosome contains several genes encoding immune and inflammatory molecules, including FOXP3, essential for regulatory T-cell development, or the TLR7, essential receptor for PAMPs and DAMPs that has been associated with CVD, including atherosclerotic plaque formation.⁷⁵ Finally, some environmental factors, such as pollution and chemotoxicity, can be intertwined with all the above and worsening inflammation.

Understanding these contributing factors is essential for developing strategies to mitigate inflammageing and its associated health risks. Ongoing research aims to unravel the complex interplay of these factors and identify potential interventions to promote healthy ageing.

6.2 Inflammageing and atherosclerosis: causes and consequences of inflammageing for atherosclerosis and treatments based on inflammageing

As individuals age, they become increasingly susceptible to cardiometabolic pathologies due to a combination of biological, physiological, and lifestyle factors.^{76,77} Among the most studied ones, inflammageing has emerged as a key pathophysiological process driving this relationship, with significant relevance in the context of atherosclerosis. Indeed, ageing is a major risk factor for atherosclerosis, presumably due to inflammageing.⁷⁸

6.3 Definition of atherosclerosis: hints on inflammageing

Atherosclerosis is an intricate vascular condition marked by the gradual build-up of lipids, inflammatory cells, and fibrous material within the subendothelial space of large arteries.⁷⁹ Despite advancements in prevention and treatment, it continues to be the foremost cause of death in developed nations.⁸⁰ Atherosclerotic lesions typically develop in branching regions of disturbed blood flow, which damage vascular endothelial cells and triggers inflammatory pathways, heightened permeability, oxidative stress, NF- κ B activity, and followed by the expression of receptors and cytokines that attract leucocytes. Compromised endothelial integrity also enables the accumulation and oxidation of cholesterol-laden LDL particles within the arterial wall which increasingly contributes to the later events such as monocyte differentiation to macrophages and transition to foam cells.⁸¹ The NLRP3 inflammasome activation in macrophages, cells responsible of clearance of cholesterol excess in the plaque through efflux, prompts the release of IL-1 β , IL-18 together with other proinflammatory cytokines, serving as chemoattractant for T and B cells, which play critical roles in the atherogenesis. Evolved atheroma encompasses a necrotic core enriched in apoptosis and senescent cells expressing p16INK4A and the tumour suppressor ARF, characterized by SASP that fosters inflammation and provokes the destabilization of the atherosclerotic plaque.¹² This intricate progression contributes significantly to the vulnerability and rupture of the plaque, the formation of thrombus, and the onset of acute vascular occlusion that might later result in a myocardial infarction or stroke.⁷⁹

6.4 Inflammageing contributing to atherosclerosis

Inflammageing not only contributes to atherosclerosis itself but also interacts with conventional cardiovascular risk factors, such as obesity, hypertension, and Type 2 diabetes mellitus, amplifying their adverse cardiovascular effects. The origins of inflammageing and its interconnection to other health outcomes are not fully understood. An ongoing debate centres around whether elevated levels of proinflammatory compounds found in circulation and tissues are causally contributing to associated pathological conditions or if inflammation merely serves as a reactive marker to the underlying pathology. Both possibilities are believed to be feasible as these mechanisms are highly interconnected.¹² This is particularly true for atherosclerosis, where early damage occurring during inflammation

Table 2 Main clinical trials of anti-inflammatory therapy in CVD

Clinical trial	Drug/compound	Molecular target	Outcome/observations
Anakinra trials ^{100,101}	Anakinra	IL-1R	Reduced systemic inflammatory status and decreased CRP levels in HFpEF patients
CANTOS trial ¹⁰²	Canakinumab	IL-1 β	Demonstrated effectiveness in reducing recurrent fatal and non-fatal cardiovascular events
CIRT trial ¹⁰³	Methotrexate	Purinergic signalling	International study exploring anti-inflammatory approaches against CVD, outcome not successful
COLCOT trial ^{104–106}	Colchicine	Inflammatory pathways	Included in ESC recommendations for prevention in high-risk CVD patients
DELIVER study ¹⁰⁷	Dapagliflozin	SGLT2	Reduced combined risk of worsening HF or CV death among HFpEF patients
EMPEROR preserved ¹⁰⁸	Empagliflozin	SGLT2	Reduced cardiovascular death or hospitalization for HF in HFpEF patients
LoDoCo trial ¹⁰⁴	Colchicine	Microtubule assembly	Reduced risk of CVD events in patients with post-myocardial infarction
LoDoCo trial 2 ^{103,109}	Colchicine	Microtubule assembly	Lowered risk of CVD events in individuals with chronic coronary disease
MEASURE study ^{98,99}	Tocilizumab	IL-6R	Targeting specific inflammatory pathways in HFpEF
PARAGON trial ¹¹⁰	LCZ696	Angiotensin-nepresylin	No significant improvement in inflammation level in HFpEF patients
STABILITY trial ^{104,111}	Darapladib	Lp-PLA2	Investigated inhibition of Lp-PLA2, outcome not successful
STEP-HFpEF trial ^{100,112}	Semaglutide	GLP-1R	Reduced inflammation in obese HFpEF patients
VISTA-16 trial ¹¹¹	sPLA2	sPLA2	Inhibition of lipid inflammatory mediator, outcome not successful

of vascular endothelial cells triggers the development of the atherosclerotic lesions, while atherosclerosis itself generates antigens and perpetuates the inflammatory response. Adding to the complexity, the crosstalk between chronic inflammation and other hallmarks of ageing such as senescence or telomere shortening during atherosclerosis, results in a vicious cycle that exacerbates the decline in cellular functions and promotes ageing.⁷⁸ Furthermore, important aspects associated with the deterioration of IS linked to ageing have been directly related to atherosclerosis. As such, mutations leading to CHIP contribute to the increased inflammation seen in ageing and partially explain the age-related risk of CVD.³⁹ Moreover, the high NLR, a marker of systemic inflammation increased during ageing, represents an independent prognostic factor for coronary artery disease and is a strong predictor of atherosclerotic carotid plaques in older adults.⁸² Additionally, recent studies in humans have shown inflammatory transcriptional reprogramming and myeloid skewing in patients with atherosclerosis.⁸³ Also, it has been reported that clonally expanded memory CD8⁺ T cells accumulate in atherosclerotic plaques and are proatherogenic in aged mice.⁸⁴ Vascular extrinsic mechanisms are reviewed in detail elsewhere.⁸⁵

Noteworthy, chronic inflammation can accelerate telomere dysfunction and cell senescence in HIV-infected population. Emerging data indicate that, even under strict control of the traditional cardiovascular risk factors, HIV infection increases rates of atherosclerosis-related disease, mostly due to chronic arterial inflammation, which, in turn, promotes atherosclerosis. In fact, young HIV-infected adults show premature biological ageing with accentuated immune activation. Chronic inflammation with excessive T-cell activation could be associated with telomere shortening, premature ageing, and subclinical atherosclerosis in young HIV-infected adults.⁸⁶ All in all, this evidence strongly suggests that atherosclerosis shares several common pathologic mechanisms with ageing and inflammaging.⁸⁷

With the aim of simplifying the complex phenomena currently describing the mechanisms and consequences of atherosclerosis, inflammaging can be seen from a cellular or systemic level perspective (Figure 2). In this sense, several circulating proinflammatory markers of inflammaging, such as IL-1 β , IL-6, CRP, and TNF- α , are considered as predicted risk factors of CVD in an ageing setting.^{88–90} High TNF- α levels in centenarians are associated with a low ankle-brachial arterial pressure index, indicating peripheral atherosclerosis.^{91,92} In agreement, genome-wide association studies (GWAS) conducted with centenarian populations from Italy and China have pinpointed polymorphisms within the IL-6 gene locus as key determinants of longevity, explaining up to 1% of lifespan variance.^{93–95} In the Italian centenarian population (InCHIANTI study), circulating levels of IL-6

and soluble TNFR1 emerged as robust predictors of inflammatory risk, with an inflammation index score proving to be a strong predictor of 10-year all-cause mortality in older individuals.⁹⁶ Notably, recent GWASs have implicated the IL-6 locus in calcific aortic valve stenosis, suggesting a link between inflammaging and this age-related CV condition.⁹⁷ Moreover, works from Ridker and others have shown that IL-6, together with IL-1, well-known contributors to the pathophysiology of atherosclerosis, represent potential therapeutic targets for the disease.⁸⁸ In line with this, impaired IL-6 signalling due to polymorphisms or the inhibition of the IL-6 receptor (IL-6R) by tocilizumab (TCZ), a blocker monoclonal antibody to treat rheumatoid arthritis, have shown significant decreased odds of coronary heart disease events in large cohorts of patients^{98,99} potentially due to reduced proinflammatory HDL-associated serum amyloid A⁴² (Table 2). The therapeutic outcome of this strategy has been further explored. A small study TOCRIVAR, for instance, demonstrated that abnormalities in the lipid profile in TCZ-treated patients correlated to levels of proprotein convertase subtilisin/kexin-9 (PCSK9), but reduced Lp(a) serum concentration and increased cholesterol efflux capacity, reinforcing a favourable effect on lipid metabolism, and consequently on cardiovascular risk.¹¹³ Aligned with the inflammatory characteristics of ageing, atherosclerosis and its acute manifestations, individuals with chronic extracardiac inflammatory conditions like rheumatoid arthritis or psoriatic arthritis exhibit an increased CVD-related mortality compared with the general population.¹¹³ Aside from IL-6, the primary circulating form of IL-1, IL-1 β , triggers atherogenic events, including smooth muscle cell (SMC) proliferation, recruitment of inflammatory cells followed by leucocyte adhesion, production of IL-6, and exerts a procoagulant activity.¹¹⁴ Indeed, the large canakinumab anti-inflammatory thrombosis outcomes study (CANTOS trial) published in 2017 in a large cohort consisting of >10 000 patients with previous myocardial infarction and high CRP has shown demonstrable effectiveness of anti-inflammatory therapy using a monoclonal antibody targeting IL-1 β and reducing recurrent fatal and non-fatal cardiovascular events¹⁰² (Table 2). Some other anti-inflammatory therapeutic approaches against CVD explored have failed, like the international study with methotrexate (CIRT trial)¹⁰³ or the VISTA-16 and the STABILITY trials that investigated the inhibition of lipid inflammatory mediator sPLA2 or Lp-PLA2, respectively.¹¹¹ Nevertheless, clinical approaches testing other compounds have shown promising effectiveness. This applies for colchicine, a drug that down-regulates several inflammatory pathways and reduces neutrophil function and migration through the vascular endothelium, both proatherogenic events linked to unstable coronary disease.¹⁰⁴ In the LoDoCo and LoDoCo Trial 2, colchicine treatment resulted in lowering the risk of CDV events in patients who have experienced a recent myocardial infarction and in individuals diagnosed with chronic coronary

disease, respectively.^{103,109} More recently, conclusions from COLCOT trial have led the European Society of Cardiology to include colchicine as a recommendation for prevention in high-risk patients of CVD^{105,106} (Table 2).

From a more experimental standpoint, a significant number of studies have highlighted the impact of inflammaging on key molecular and cellular mechanisms occurring or contributing to atherogenesis. That is the case for hypertension in older individuals, where inflammatory mediators contribute to the dysfunction of vascular endothelial cells (ECs) and vascular smooth muscle cells (VSMCs). In experimental hypertension, the presence of inflammatory cells such as dendritic cells, NK cells, and macrophages is typical.¹¹⁵ Monocytes expressing receptors for Angiotensin II and mineralocorticoids drive hypertension by promoting inflammatory polarization and increasing ROS production.¹¹⁶ The context of inflammaging amplifies these effects, with macrophages in the vessel wall generating higher ROS levels, which leads to reduced nitric oxide (NO) availability, increased adhesion molecule expression, VSMC hypertrophy, and activation of MMPs, contributing to vascular remodelling and dysfunction.¹¹⁷ Mice with functionally deficient macrophages exhibit reduced vascular oxidative stress, improved endothelial function, and resistance to hypertension.¹¹⁸ Mediators of inflammaging, including TNF, IL-1 β , Caspase 1, and components of NLRP3 inflammasome, are potential targets for age-related hypertension that hastens the formation of atherosclerotic plaque.¹¹⁹ In addition, cholesterol crystals activate the NLRP3 inflammasome in macrophages, leading to the release of proinflammatory cytokines, further fuelling the inflammatory response associated with atherosclerosis. In this line, lipid intermediates, such as cholesterol, play a pivotal role in connecting inflammaging and atherosclerosis and related events orchestrated by immune cells like macrophages and lymphocytes within the atherosclerotic plaque. As indicated before, the accumulation of LDL-cholesterol within arterial walls represents a key event during atherogenesis, which triggers inflammation, engaging T cells, and promoting the formation of atherosclerotic plaques. A recent study provides additional clues regarding the existing crosstalk between lipid pathways, inflammaging, and atherosclerosis. The Westertep group's demonstrated that T-cell-specific deficiency in cholesterol efflux transporters *Abca1* and *Abcg1* led to increased T-cell activation, apoptosis, and premature ageing, ultimately contributing to increased atherogenesis in middle-aged mice.¹²⁰ These findings shed light on the role of the adaptive IS and lipid pathways in age-related inflammation and atherosclerosis, potentially offering new insights for therapeutic interventions in ageing individuals. In agreement with this, the lipidome changes associated with ageing might be relevant as they can reflect the progressive deterioration of metabolic health and contribute to age-related pathologies. Hornburg *et al.*,¹²¹ reported changes in >800 lipid species in human plasma, many of which are associated with health-to-disease transitions in diabetes, ageing and inflammation, as well as cytokine–lipidome networks. The researchers observed a shift in the physicochemical properties of lipids, including increased levels of saturated fatty acids and monounsaturated fatty acids and reduced levels of polyunsaturated fatty acids (PUFAs). This pattern has been associated with dyslipidaemia and inflammation, indicating progressive deterioration of cardiometabolic health during ageing.¹²² Additionally, depleted levels of beneficial omega-3 fatty acids, such as docosahexaenoic acid and eicosapentaenoic acid, were observed with ageing. Some other specialized mediators derived from PUFAs, proresolvins, have gained increasing interest as a potential therapeutic target for inflammaging and its associated pathologies. Although bibliography has not provided specific findings in the context of age-related CVD, significant reduced levels of resolvin D1 have been found in vulnerable regions of atherosclerotic plaques, particularly where macrophages express 5-lipoxygenase. This enzyme converts arachidonic acid to proinflammatory leukotrienes, suggesting a potential role in promoting plaque rupture.¹²³ Nevertheless, the discovery of factors that integrate synergistic effects contributing to atherosclerosis, such as inflammatory and lipid metabolic factors or biomechanical effects, will help to better understand the linking between atherosclerosis and ageing. Caveolin-1 (Cav-1) for instance, a structural protein cholesterol-enriched membrane rafts known as caveolae,¹²⁴ is known to be necessary for the development of atherogenesis by enhancing LDL transcytosis, EC vascular

inflammation, and modulation of ECM remodelling.⁷⁹ Interestingly, Cav-1 has been shown to play a critical role in vascular ageing *in vivo*, regulating dyslipidaemia and disturbed flow and promoting endothelial stiffening induced by oxidized-LDL *in vitro*.¹²⁵ Moreover, Cav-1 deficiency also enhances autophagy in the aortic endothelium, a recognized age-associated mechanism thereby mitigating vascular ageing and atherosclerosis.⁸¹ Altogether, previous studies suggest a therapeutic avenue for managing several aspects of vascular ageing and atherosclerosis through modulation of Cav-1 expression.

6.5 miRNAs in atherosclerosis and inflammaging

Epigenetic alterations, encompassing DNA methylation, modifications to histones, and post-transcriptional regulators, such as miRNAs or RNA-binding proteins, are associated with the control of inflammatory pathways and processes related to ageing (Figure 2). A growing number of reports have shown the capacity of miRNAs to target effectors of longevity or stem cell behavior^{1,126} or other aspects closely associated with age-related CVD, such as lipid metabolism and inflammation.^{127,128} Although our understanding of their involvement in atherosclerosis and cardiovascular metabolism is more comprehensive,¹²⁹ further research is required to precisely elucidate how these post-transcriptional regulators synergistically contribute to both inflammaging and atherosclerosis. MiRNAs have emerged as direct modulators of inflammatory pathways, including NF- κ B, mTOR, Sirt, TGF- β , and differential patterns of miRNA signatures are linked to age-related diseases, including atherosclerosis.^{130,131} Conducted research showed up-regulated miRNAs such miR-21-5p and miR-126-3p during ageing while others like miR-25-3p, miR-92a-3p, miR-93-5p, miR-101-3p, miR-106b-5p, miR-142-5p, miR-151a-3p, and miR-181a-5p are reduced levels in age individuals. Some other up-regulated miRNAs present in circulating plasma and extracellular vesicles, such as miR-29a-3p, miR-29c-3p, miR-155-5p, miR-184-3p, or miR-300-3p, have been lately described as systemic regulators of ageing. Despite the available information, the promiscuous nature of the regulation of gene expression by miRNAs makes it necessary to explore direct actions on specific pathways or targets involved in inflammation in the context of age-induced atherosclerosis. For instance, miR-21-5p levels are higher in patients with CVD than in age-matched controls and inversely correlate to circulating inflammatory markers of CVD, such as CRP or fibrinogen.¹³² Another example is miR-34, which has emerged a key gero-miRNA, increasing with age and promoting senescence and inflammation in vascular cells. Indeed, various risk factors of CVD modulate miR-34a expression, exacerbating vascular dysfunction or promoting VSMC proliferation during disease progression.¹⁰⁷ To add further intricacy to the field, patterns of molecular changes in miRNAs during ageing seems to be tissue- and cell-type specific,^{131,133} that, summed to the complex multicellularity of the atherosclerotic process, makes these studies very challenging. Nevertheless, approaches as experimental heterochronic parabiosis have been able to partially reverse the age-related increase in miR-29c-3p, a miRNA that targets ECM and secretion pathways which could potentially impact inflammaging and CVD.¹³¹ Related to the inflammatory nature of miRNAs during ageing, studies analysing whole-blood human samples suggest that the miRNAs showing an increase with age primarily originated from immune cells, including B cells, monocytes, NK cells, and cytotoxic T cells. Moreover, analysis of large cohort of patients uncovered pan-disease and disease-specific alterations in ageing miRNA profiles. Specifically, miRNAs, such as miR-191-5p and miR-16-5p, were highlighted as dysregulated in the context of cardiovascular disorders, suggesting their potential involvement in the underlying molecular mechanisms.¹³¹

These findings provide insights into the complex dynamics of miRNA changes during ageing and their potential implications for understanding age-related cardiovascular disorders and developing specific disease biomarkers. In summary, the identification of disease biomarker sets in ageing profiles has the potential to revolutionize the diagnosis, treatment, and management of age-related diseases, ultimately improving the quality of life for older patients.

The acknowledgement of the interconnected relationship between ageing, inflammation, and CVD has garnered significant new mechanistic insights, as

outlined in this section. Several innovative therapeutic possibilities have arisen from these advancements in basic science. Utilizing biomarkers to evaluate the heightened activity of specific proinflammatory pathways could aid in tailoring therapies and improving the personalization of medical interventions, particularly in the expanding aged population.

6.6 Heart failure with preserved ejection fraction and inflammaging

The molecular mechanisms of inflammaging in cardiac and vascular ageing involve several key pathways and processes including the NLRP3 inflammasome activation and the interaction with TGF- β 1 axis, telomere shortening, oxidative stress, and endothelial dysfunction among others (Figure 2).¹³⁴ These altered inflammation processes impact in CVDs other than atherosclerosis such as HF disease, hypertension, and degenerative aortic aneurysm. HF with preserved ejection fraction (HFpEF) is a condition that affects over 50% of HF patients where the heart is unable to pump blood effectively, leading to a range of symptoms, such as fatigue, shortness of breath, and fluid retention. Despite in HFpEF, the ejection fraction is preserved, meaning that the heart's pumping function is still relatively normal, patients with HFpEF display abnormal diastolic fraction.¹³⁵ This results in elevated pressures within the heart, leading to symptoms of HF. There are several risk factors for HFpEF but compared with HF-reduced ejection fraction (HFrEF), in which the ejection fraction is reduced, HFpEF is more often associated with conditions such as hypertension, obesity, diabetes, insulin resistance, and ageing.^{135,136} In fact, available evidence suggests that the severity of HFpEF increases more rapidly with age than HFrEF but also the prevalence of HFpEF at any given age is higher in women compared with men, suggesting a close interplay between ageing, gender, and age-related HFpEF progression compared with HFrEF.¹³⁷ Moreover, metabolic dysfunction is a feature of ageing, and a large proportion of HFpEF individuals is overweight or obese and display metabolic cardiomyopathy. Clinical and preclinical studies have linked adiposity with deteriorating cardio-pulmonary parameters in HFpEF.¹³⁸

In this section of the review, we explore the molecular and pathological settings by which inflammaging may be both a risk factor and a pathogenic mechanism of HFpEF and identifies potential targets, specifically those that are based on anti-inflammaging strategies. Inflammaging plays a causative role in the development of HFpEF which is disproportionately found in older individuals. Several key inflammatory pathways are involved in HFpEF, including chronic low-grade systemic inflammation, activation of the renin-angiotensin-aldosterone system, oxidative stress, and activation of the IS. These pathways can contribute to the development and progression of HFpEF and its associated comorbidities. Inflammaging may also induce changes in the vasculature of the heart.¹³⁹ Specifically, by reducing availability of NO, an important vasodilator and regulator of protein kinase G activity causing hypertrophic changes and endothelial production of E-selectin. This results in an increase of lymphocytes recruitment which in turn release TGF- β 1, encouraging fibrosis and thus ventricular stiffening, all of which can worsen diastolic function. Activation of the renin-angiotensin-aldosterone system can also contribute to fibrosis and hypertrophy of the heart, while oxidative stress can lead to metabolic heart disease. Recent evidence shows that PCSK9 has emerged as a new regulator of cardiometabolic ageing as their levels are increased in older people and is an independent predictor of left ventricle diastolic dysfunction.¹⁴⁰ On the other hand, cardiac ageing increases cardiomyocyte senescence that affects normal function of heart resembling HFpEF manifestations.¹⁰⁸ It has been suggested that HFpEF merely represents an acceleration of a normal ageing process. In fact, senile systemic amyloid deposition as part of the degenerative ageing process is emerging as a prominent and underdiagnosed contributor to HFpEF with age (Figure 2). Lately, activation of the IS by all these stressors and other events, such as previous infections, particularly with CMV and HIV can also contribute to the development progression and perpetuation of HFpEF and its associated comorbidities through inflammaging. In this context, due to the chronic or persistent antigen stimulation, T-cell responses are compromised during ageing at least partially owed to immunosenescence and inflammation as hypothesized by Sansoni et al.¹⁴¹

Managing HFpEF typically involves addressing underlying conditions, lifestyle modifications, and medications to alleviate symptoms and improve the overall function of the heart.^{142,143} Efficacy of common HF therapeutics has turned unsatisfactory in HFpEF so far. Specific therapeutic strategies for HFpEF treatment include drug repurposing, targeting metabolic-induced inflammation, and ongoing clinical trials testing various pharmacological therapies with immunomodulatory actions for CVD and diverse HF. Regarding available targeted metabolic dysfunction interventions, which are the most, some of them have beneficial effects in inflammatory status of HFpEF. Clinical trials testing other targets and device-based approaches in HFpEF are also being explored. Among them, direct targeting of inflammaging offers a new therapeutic opportunity for HFpEF patients.

6.7 Targeting low chronic inflammation for HFpEF treatment

Different inflammatory pathways converge in the onset of inflammaging as discussed above; therefore, attenuation of inflammatory burden during ageing may attenuate the severity of symptoms observed in HFpEF patients, which in turn can enhance the quality of life and life expectancy. Immunomodulatory therapies, such as monoclonal antibodies targeting proinflammatory cytokines, are the most used. The activation of NLRP3 inflammasome signalling in HFpEF remains circumstantial and requires further investigations. In contrast to other CVD events, such as atherosclerosis, canakinumab has not been tested in HFpEF patients yet.¹⁰² However, several trials aiming to inhibit cardiac proinflammatory pathways in HFpEF, by blockade of IL-1R with anakinra, a recombinant IL-1 receptor antagonist, resulted in reduced systemic inflammatory status and decreased CRP levels.^{100,101} Because of elevated levels of systemic IL-6 and TNF- α in HFpEF patients, targeting these specific inflammatory pathways with anti-IL-6 therapy (TCZ) and anti-TNF- α , respectively, represents the best examples of immunomodulatory strategies¹⁴⁴ (Table 2). These cytokines, together with CRP, have also proved useful as robust biomarkers to identify patients who may benefit from anti-inflammatory treatments. The potential benefits of TNF- α antagonism in rescuing the effects of ageing on stroke are shown in a study that offers exciting perspectives for targeting inflammaging and improving stroke outcomes and other HF diseases.¹⁴⁵ In another study, treatment with a DC-SIGN ligand (DCSL1, dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin ligand 1) reduced macrophage polarization and diastolic dysfunction during ageing, but in a gender-specific manner.¹⁴⁶ The reduction in proinflammatory macrophage polarization was accompanied by a decrease in fibrosis, suggesting that the anti-inflammatory effects of DCSL1 may have contributed to the improvement in diastolic function in female mice. On the other hand, colchicine has been shown to have anti-inflammatory properties in a high salt diet rat model of HFpEF, attenuating cardiac dysfunction and fibrosis and modulating the inflammasome NLRP3 and NF- κ B pathways.¹⁴⁷ Several clinical trials have been conducted on colchicine in reducing cardiovascular events in diverse heart disease and CVD, including atherosclerosis; however, despite the promising results of colchicine in animal models, its use in humans should be carefully considered because of certain side effects. Even so, low doses in humans are only recommended to high CVD-risk patients.^{105,106}

Since there is a strong correlation between HFpEF and metabolic syndrome, T2D, and obesity, available therapeutic strategies for these diseases are now being evaluated to prevent or manage diverse pathological aspects of heart disease and specifically HFpEF. Some of these metabolic interventions using inhibitors with indirect beneficial effects on the inflammatory status of HFpEF, include trials testing sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors), a monoamine oxidase inhibitor,¹⁴⁸ a xanthine oxidase inhibitor,¹⁴⁹ and an inhibitor of the uric acid transporter URAT1.¹⁵⁰ While the empagliflozin SGLT2 inhibitor has turned out to be beneficial and showed significant changes in cognitive impairments and frailty,¹⁵¹ it has not been tested yet for inflammaging in HFpEF disease.⁹⁴ However, another SGLT2 inhibitor, dapagliflozin, also used in the treatment of T2D, resulted in improvement of HFpEF as indicated by

reduced hospitalizations and cardiovascular death¹⁵² (Table 2). In this line, a recent study provides new clues about the metabolic stress-dependent activation of cardiac macrophages in a model of dyslipidaemia-induced diastolic dysfunction, putting the IS back in the spotlight as a target for treatment HFpEF. In this study, the authors suggest the use of SLTG2 inhibitors as potential agents in the therapy of this specific phenotype of HFpEF. Other pharmacological treatments mainly used for non-alcoholic fatty liver disease, including statins, thiazolidinediones, GLP-1R agonists, and metformin, have shown beneficial effects on HFpEF progression but whether this mechanism involves reduction of inflammaging has not been addressed yet. Recently, semaglutide has gained increasing interest in targeting diabetes and other metabolic dysfunction. This GLP-1R agonist is approved in obese HFpEF patients' treatment and may reduce inflammation at the systemic level by measuring CRP levels as shown in the STEP-HFpEF trial.^{112,153}

The use of angiotensin receptor neprilysin inhibitors may exert its therapeutic effects in HFpEF by targeting multiple pathological mechanisms involved in the pathogenesis and progression of the condition, including inflammation, hypertrophy, and fibrosis. One of them, sacubitril/valsartan reduces myocardial inflammation¹⁵⁴ while LCZ696 inhibitor used in other trial (PARAGON) for HFpEF patients,¹¹⁰ did not show any significant improvement at the inflammation level, except in some specific cases of HFpEF. The use of different angiotensin inhibitor therapeutic agents has revealed heterogeneity in the symptoms of this disease. Therefore, more evidence is needed to clarify the exact mechanism by which some individual respond better than others.

Other evidence suggests that stimulators of the NO-sensitive soluble guanylyl cyclase could be a potential therapeutic option for humans with HFpEF. A study shows that using the NO-independent stimulator BAY 41-8543 in a double-transgenic rat model of HFpEF can drastically improve survival rates, reduce cardiac fibrosis and inflammation, and improve cardiac function and hemodynamics.¹⁵⁵ Thus, future studies are necessary to determine the interplay between senescence mechanisms and metabolic-induced inflammation for the HFpEF pathogenesis.

Finally, another interesting strategy is based on targeting the mitochondria-inflammation circuit to mitigate HFpEF. By increasing circulating β -hydroxybutyrate abundance, it ameliorates HFpEF phenotypes by abrogating the vicious circuit of mitochondrial damage and inflammation. The study investigates metabolic mechanisms and tests therapeutic interventions of HFpEF by revealing new mechanisms between mitochondrial dysfunction and activation of NLRP3 inflammasome as a key driver in the pathogenesis of HFpEF.¹⁵⁶

6.8 Nutritional and lifestyle-based interventions with reduced inflammaging

There is ample evidence that western lifestyle in the developed world in combination with environmental triggers increases cardiovascular risk of the world's population as it age. A sedentary lifestyle, hypercaloric diets or stress may accelerate or worsen the symptoms of CVD.¹⁵⁷ For example, recent evidence showed association of non-regular sleep and sub-clinical markers of CVD, with special impact on atherosclerosis.¹⁵⁸ There is a variety of lifestyle modifications based on reduced dietary intake, and their pharmacological mimics, that delay the onset of age-related diseases and expand life expectancy. Nutrient sensors, such as mTOR and its downstream mediator Syntaxin 13 (Syx13), are linked to lysosome morphology and regulate inflammaging as shown in a recent study.¹⁵⁹ Of note, rapamycin treatment reduced inflammaging and immunosenescence. Therefore, distinct interventions other than the use of medications are being developed to mitigate inflammaging and therefore the onset and progression of its associated diseases. The role of nutrition is a key on inflammaging status as described by many authors and it is clear that specific modifications in dietary patterns that affects inflammaging have become in a powerful strategy for healthy ageing.^{160,161} Additionally, natural non-drug intervention based on regular exercise are now being explored in several trials to test whether inflammatory markers are reduced. As shown in this recent work,¹⁶² in addition to positive impact delaying the onset of

age-related diseases, exercise has been shown to enhance proteostasis, stress response, and epigenetic stability, while reducing inflammation and metabolic dysregulation. Previous studies have demonstrated higher levels of proinflammatory eicosanoids in HF, including prostaglandins PGI₂ and PGE₂, suggesting their involvement in the inflammatory processes underlying HFpEF.¹⁶³ Some of these lipids act as ideal biomarkers of HFpEF status and exercise manifestations in the disease. Therefore, targeting these bioactive lipid mediators could be a therapeutic strategy to modulate inflammation in the physiopathology of HFpEF.¹⁶⁴

Malandish and Gulati investigated the effects of exercise interventions on serum or plasma levels of specific inflammaging markers (TNF- α , IL-6, IL-1 β , IL-8, and high-sensitivity CRP, hs-CRP) in overweight and obese patients with HFpEF. The study revealed significant differences in the effects of aerobic, resistance, and concurrent exercises on inflammaging markers in overweight/obesity patients with HF, specifically improving inflammaging markers such as TNF- α , IL-6, and hs-CRP. In addition, the analysis of subgroups by age, body mass index (BMI), type, intensity, duration of exercise, and mean left ventricular ejection fraction revealed specific reductions in TNF- α , IL-6, and hs-CRP for different exercise modalities and patient's characteristics. Furthermore, the meta-analysis highlighted that aerobic and concurrent interventions with moderate and high exercise intensities, as well as short, long, and very long-term follow-ups, may down-regulate the inflammaging process in HF patients. These findings suggest that the type and intensity of exercise interventions, as well as the duration of follow-up, play a significant role in modifying inflammaging markers in overweight/obesity patients with HF.¹⁶⁵ These findings have several potential implications for the development of exercise interventions for patients with HF and related conditions including tailored exercise prescription and the anti-inflammaging effect of the exercise prescription, which may have clinical benefits for patients with HF. The findings call for further research to explore how exercise interventions, ageing, and BMI modify the inflammaging process in individuals with HF. Overall, the data described in this review provide new approaches on how to treat CVD and present strategies to prevent atherosclerosis and HF, both based in modifying inflammaging markers and improving clinical outcomes for patients with HF and obesity. Lastly, all these analyses can help to improve or even delay the ageing process.

Acknowledgements

The authors thank Carlos Anerillas for critical discussion of the manuscript.

Funding

This work was funded/co-funded by the European Union (ERC, Let T Be, ERC-2021-CoG 101044248). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Council. Neither the European Union nor the granting authority can be held responsible for them. This work was funded/co-funded by Grant PID2022 1411690B-I00 funded by MICIU/AEI/10.13039/501100011033 and, by 'ESF Investing in your future', Y2020/BIO-6350 NutriSION-CM synergy from Comunidad de Madrid (Spain) grants to M.M. and by PID2021-128264OB-I00 funded by MCIN/AEI/10.13039/501100011033 and 'ERDF A way of making Europe' by the European Union to C.M.R.

Conflict of interest: none declared.

Data availability

Not applicable.

References

- Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. *Cell* 2023;**186**:243–278.
- Clegg A, Young J, Illife S, Rikkert MO, Rockwood K. Frailty in elderly people. *Lancet* 2013;**381**:752–762.
- Fontana L, Partridge L. Promoting health and longevity through diet: from model organisms to humans. *Cell* 2015;**161**:106–118.

4. Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, Ferrucci L, Gilroy DW, Fasano A, Miller GW, Miller AH, Mantovani A, Weyand CM, Barzilai N, Goronzy JJ, Rando TA, Effros RB, Lucia A, Kleinstreuer N, Slavich GM. Chronic inflammation in the etiology of disease across the life span. *Nat Med* 2019;**25**:1822–1832.
5. Boraschi D, Aguado MT, Dutel C, Goronzy J, Louis J, Grubeck-Loebenstain B, Rappuoli R, Del Giudice G. The gracefully aging immune system. *Sci Transl Med* 2013;**5**:185ps188.
6. Mercken EM, Capri M, Carboneau BA, Conte M, Heidler J, Santoro A, Martin-Montalvo A, Gonzalez-Freire M, Khraiwesh H, Gonzalez-Reyes JA, Moaddel R, Zhang Y, Becker KG, Villalba JM, Mattison JA, Wittig I, Franceschi C, de Cabo R. Conserved and species-specific molecular denominators in mammalian skeletal muscle aging. *NPJ Aging Mech Dis* 2017;**3**:8.
7. Sayed N, Huang Y, Nguyen K, Krejcirova-Rajaniemi Z, Grawe AP, Gao T, Tibshirani R, Hastie T, Alpert A, Cui L, Kuznetsova T, Rosenberg-Hasson Y, Ostan R, Monti D, Lhahliar B, Shen-Orr SS, Maecker HT, Dekker CL, Wyss-Coray T, Franceschi C, Jovic V, Haddad F, Montoya JG, Wu JC, Davis MM, Furman D. An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging. *Nat Aging* 2021;**1**:598–615.
8. Hirata T, Arai Y, Yuasa S, Abe Y, Takayama M, Sasaki T, Kunitomi A, Inagaki H, Endo M, Morinaga J, Yoshimura K, Adachi T, Oike Y, Takebayashi T, Okano H, Hirose N. Associations of cardiovascular biomarkers and plasma albumin with exceptional survival to the highest ages. *Nat Commun* 2020;**11**:3820.
9. Furman D, Chang J, Lartigue L, Bolen CR, Haddad F, Gaudilliere B, Ganio EA, Fragiadakis GK, Spitzer MH, Douchet I, Daburon S, Moreau JF, Nolan GP, Blanco P, Dechanet-Merville J, Dekker CL, Jovic V, Kuo CJ, Davis MM, Faustin B. Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states. *Nat Med* 2017;**23**:174–184.
10. Gabandé-Rodríguez E, Soto-Heredero G, Carrasco E, Anerillas C, Escrig-Larena JJ, Delgado-Pulido S, Francos-Quijorna I, Gómez de las Heras MM, Fernández-Almeida Á, Blanco EM, Winand-Osete E, Zorita V, Martínez-Cano J, Garrido A, Cabo RD, Mañes S, Gorospe M, Mittelbrunn M. Cytotoxic CD4+ T cells in the bone marrow compromise healthy ageing by enhancing granulopoiesis. *bioRxiv* 2024:2024.2001.2026.577360.
11. Li J, Yao Z, Liu X, Duan R, Yi X, Ayoub A, Sanders JO, Mesfin A, Xing L, Boyce BF. TGFβ1(+)/CCR5(+) neutrophil subset increases in bone marrow and causes age-related osteoporosis in male mice. *Nat Commun* 2023;**14**:159.
12. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. *Nat Rev Cardiol* 2018;**15**:505–522.
13. Baechele JJ, Chen N, Makhijani P, Winer S, Furman D, Winer DA. Chronic inflammation and the hallmarks of aging. *Mol Metab* 2023;**74**:101755.
14. Hashimoto K, Kouno T, Ikawa T, Hayatsu N, Miyajima Y, Yabukami H, Terooatea T, Sasaki T, Suzuki T, Valentine M, Pascarella G, Okazaki Y, Suzuki H, Shin JW, Minoda A, Taniuchi I, Okano H, Arai Y, Hirose N, Carninci P. Single-cell transcriptomics reveals expansion of cytotoxic CD4 T cells in supercentenarians. *Proc Natl Acad Sci U S A* 2019;**116**:24242–24251.
15. Abplanalp WT, Cremer S, John D, Hoffmann J, Schuhmacher B, Merten M, Rieger MA, Vasa-Nicotera M, Zeiher AM, Dimmeler S. Clonal hematopoiesis-driver DNMT3A mutations alter immune cells in heart failure. *Circ Res* 2021;**128**:216–228.
16. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardissino D, Baber U, Mehran R, Fuster V, Danesh J, Frossard P, Saleheen D, Melander O, Sukhova GK, Neuberg D, Libby P, Kathiresan S, Ebert BL. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. *N Engl J Med* 2017;**377**:1111–121.
17. Barkaway A, Rolas L, Joulia R, Bodkin J, Lenn T, Owen-Woods C, Reglero-Real N, Stein M, Vazquez-Martinez L, Girbl T, Poston RN, Golding M, Saleeb RS, Thiriot A, von Andrian UH, Duchene J, Voisin MB, Bishop CL, Voehringer D, Roers A, Rot A, Lammermann T, Nourshargh S. Age-related changes in the local milieu of inflamed tissues cause aberrant neutrophil trafficking and subsequent remote organ damage. *Immunity* 2021;**54**:1494–1510.e1497.
18. Lagnado A, Leslie J, Ruchaud-Sparagano MH, Victorelli S, Hirsova P, Ogronik M, Collins AL, Vizioli MG, Habiballa L, Saretzki G, Evans SA, Salmonowicz H, Hruby A, Geh D, Pavelko KD, Dolan D, Reeves HL, Grellscheid S, Wilson CH, Pandanaboyana S, Doolittle M, von Zglinicki T, Oakley F, Gallage S, Wilson CL, Birch J, Carroll B, Chapman J, Heikenwalder M, Neretti N, Khosla S, Masuda CA, Tchkonja T, Kirkland JL, Jurk D, Mann DA, Passos JF. Neutrophils induce paracrine telomere dysfunction and senescence in ROS-dependent manner. *EMBO J* 2021;**40**:e106048.
19. Desdin-Mico G, Soto-Heredero G, Aranda JF, Oller J, Carrasco E, Gabandé-Rodríguez E, Blanco EM, Alfranca A, Cusso L, Desco M, Ibanez B, Gortazar AR, Fernandez-Marcos P, Navarro MN, Hernaez B, Alcamí A, Baixauli F, Mittelbrunn M. T cells with dysfunctional mitochondria induce multimorbidity and premature senescence. *Science* 2020;**368**:1371–1376.
20. Yousefzadeh MJ, Flores RR, Zhu Y, Schmiechen ZC, Brooks RW, Trussoni CE, Cui Y, Angelini L, Lee KA, McGowan SJ, Burrack AL, Wang D, Dong Q, Lu A, Sano T, O'Kelly RD, McGuckian CA, Kato JJ, Bank MP, Wade EA, Pillai SPS, Klug J, Ladiges WC, Burd CE, Lewis SE, LaRusso NF, Vo NV, Wang Y, Kelley EE, Huard J, Stromnes IM, Robbins PD, Niedernhofer LJ. An aged immune system drives senescence and ageing of solid organs. *Nature* 2021;**594**:100–105.
21. Thomas R, Oh J, Wang W, Su DM. Thymic atrophy creates holes in Treg-mediated immuno-regulation via impairment of an antigen-specific clone. *Immunology* 2021;**163**:478–492.
22. Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, Wu CL, Sano S, Muralidharan S, Rius C, Vuong J, Jacob S, Muralidhar V, Robertson AA, Cooper MA, Andres V, Hirschi KK, Martin KA, Walsh K. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. *Science* 2017;**355**:842–847.
23. Svensson EC, Madar A, Campbell CD, He Y, Sultan M, Healey ML, Xu H, D'Acò K, Fernandez A, Wache-Mainier C, Libby P, Ridker PM, Beste MT, Basson CT. TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial. *JAMA Cardiol* 2022;**7**:521–528.
24. Di Micco R, Krizhanovsky V, Baker D, d'Adda di Fagnagna F. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. *Nat Rev Mol Cell Biol* 2021;**22**:75–95.
25. Mi T, Soerens AG, Alli S, Kang TG, Vasandan AB, Wang Z, Vezys V, Kimura S, Iacobucci I, Baylin SB, Jones PA, Hiner C, Mueller A, Goldstein H, Mullighan CG, Zebley CC, Masopust D, Youngblood B. Conserved epigenetic hallmarks of T cell aging during immunity and malignancy. *Nat Aging* 2024;**4**:1053–1063.
26. Chaib S, Lopez-Dominguez JA, Lalinde-Gutierrez M, Prats N, Marin I, Boix O, Garcia-Garajo A, Meyer K, Munoz MI, Aguilera M, Mateo L, Stephan-Otto Attolini C, Llanos S, Perez-Ramos S, Escorihuela M, Al-Shahrouf F, Cash TP, Tchkonja T, Kirkland JL, Abad M, Gros A, Arribas J, Serrano M. The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2. *Nat Cancer* 2024;**5**:448–462.
27. Medina CB, Mehrotra P, Arandjelovic S, Perry JSA, Guo Y, Morioka S, Barron B, Walk SF, Ghesquiere B, Krupnick AS, Lorenz U, Ravichandran KS. Metabolites released from apoptotic cells act as tissue messengers. *Nature* 2020;**580**:130–135.
28. Gasparini D, Wensveen FM, Turk Wensveen T. Inflammageing mediated by cytotoxic lymphocytes is associated with diabetes duration. *Diabetes Res Clin Pract* 2024;**207**:111056.
29. Murphy MP, O'Neill LAJ. A break in mitochondrial endosymbiosis as a basis for inflammatory diseases. *Nature* 2024;**626**:271–279.
30. Ingelsson B, Soderberg D, Strid T, Soderberg A, Bergh AC, Loitto V, Lotfi K, Segelmark M, Spyrou G, Rosen A. Lymphocytes eject interferogenic mitochondrial DNA webs in response to CpG and non-CpG oligodeoxynucleotides of class C. *Proc Natl Acad Sci U S A* 2018;**115**:E478–E487.
31. Fujiwara H, Seike K, Brooks MD, Mathew AV, Kovalenko I, Pal A, Lee HJ, Peltier D, Kim S, Liu C, Oravec-Wilson K, Li L, Sun Y, Byun J, Maeda Y, Wicha MS, Saunders TL, Rehemtulla A, Lyssiotis CA, Pennathur S, Reddy P. Mitochondrial complex II in intestinal epithelial cells regulates T cell-mediated immunopathology. *Nat Immunol* 2021;**22**:1440–1451.
32. Prochnicki T, Vasconcelos MB, Robinson KS, Mangan MSJ, De Graaf D, Shkarina K, Lovotti M, Standke L, Kaiser R, Stahl R, Duthie FG, Rothe M, Antonova K, Jenster LM, Lau ZH, Rosing S, Mirza N, Gottschild C, Wachten D, Gunther C, Kufer TA, Schmidt FI, Zhong FL, Latz E. Mitochondrial damage activates the NLRP10 inflammasome. *Nat Immunol* 2023;**24**:595–603.
33. Zecchini V, Paupé V, Herranz-Montoya I, Janssen J, Wortel IMN, Morris JL, Ferguson A, Chowdry SR, Segarra-Mondejar M, Costa ASH, Pereira GC, Tronci L, Young T, Nikitopoulou E, Yang M, Bihary D, Caicci F, Nagashima S, Speed A, Boeka K, Baig Z, Samarajiva S, Tran M, Mitchell T, Johnson M, Prudent J, Frezza C. Fumarate induces vesicular release of mtDNA to drive innate immunity. *Nature* 2023;**615**:499–506.
34. Pinti M, Cevenini E, Nasi M, De Biasi S, Salvioli S, Monti D, Benatti S, Gibellini L, Cotichini R, Stazi MA, Trenti T, Franceschi C, Cossarizza A. Circulating mitochondrial DNA increases with age and is a familial trait: implications for “inflamm-aging”. *Eur J Immunol* 2014;**44**:1552–1562.
35. Weiss E, Kretschmer D. Formyl-peptide receptors in infection, inflammation, and cancer. *Trends Immunol* 2018;**39**:815–829.
36. Tigano M, Vargas DC, Tremblay-Belzile S, Fu Y, Sfeir A. Nuclear sensing of breaks in mitochondrial DNA enhances immune surveillance. *Nature* 2021;**591**:477–481.
37. Martínez-Reyes I, Chandel NS. Mitochondrial TCA cycle metabolites control physiology and disease. *Nat Commun* 2020;**11**:102.
38. Arts RJ, Novakovic B, Ter Horst R, Carvalho A, Bekkering S, Lachmandas E, Rodrigues F, Silvestre R, Cheng SC, Wang SY, Habibi E, Goncalves LG, Mesquita I, Cunha C, van Laarhoven A, van de Veerdonk FL, Williams DL, van der Meer JW, Logie C, O'Neill LA, Dinarello CA, Riksen NP, van Crevel R, Clish C, Notebaart RA, Joosten LA, Stunnenberg HG, Xavier RJ, Netea MG. Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity. *Cell Metab* 2016;**24**:807–819.
39. Jaiswal S, Libby P. Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease. *Nat Rev Cardiol* 2020;**17**:137–144.
40. Caiado F, Kovtonyuk LV, Gonullu NG, Fullin J, Boettcher S, Manz MG. Aging drives tet2+/- clonal hematopoiesis via IL-1 signaling. *Blood* 2023;**141**:886–903.
41. Rafiq S, Stevens K, Hurst AJ, Murray A, Henley W, Wveedon MN, Bandinelli S, Corsi AM, Guralnik JM, Ferrucci L, Melzer D, Fraying TM. Common genetic variation in the gene encoding interleukin-1-receptor antagonist (IL-1RA) is associated with altered circulating IL-1RA levels. *Genes Immun* 2007;**8**:344–351.
42. IL6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, Gao P, Saleheen D, Rendon A, Nelson CP, Braund PS, Hall AS, Chasman DI, Tybjaerg-Hansen A, Chambers JC, Benjamin EJ, Franks PW, Clarke R, Wilde AA, Trip MD, Steri M, Wittman JC, Qi L, van der Schoot CE, de Faire U, Erdmann J, Stringham HM, Koenig W, Rader DJ, Melzer D, Reich D, Psaty BM, Kleber ME, Panagiotakos DB, Willeit J, Wennberg P, Woodward M, Adamovic S, Rimm EB, Meade TW, Gillum RF, Shaffer JA, Hofman A, Onat A, Sundstrom J, Wassertheil-Smoller S, Mellstrom D, Gallacher J, Cushman M, Tracy RP, Kauhanen J, Karlsson M, Salonen JT, Wilhelmsen L, Amouyel P, Cantin B, Best LG, Ben-Shlomo Y, Manson JE, Davey-Smith G, de Bakker PI, O'Donnell CJ, Wilson JF, Wilson AG, Assimes TL, Jansson JO, Ohlsson C, Tivesten A, Ljunggren O, Reilly MP, Hamsten A, Ingelsson E, Cambien F, Hung J, Thomas GN, Boehnke M, Schunkert H,

- Asselbergs FW, Kastelein JJ, Gudnason V, Salomaa V, Harris TB, Kooneer JS, Allin KH, Nordestgaard BG, Hopewell JC, Goodall AH, Ridker PM, Holm H, Watkins H, Ouwehand WH, Samani NJ, Kaptoge S, Di Angelantonio E, Harari O, Danesh J. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. *Lancet* 2012;**379**:1205–1213.
43. Dehghan A, Dupuis J, Barbalic M, Bis JC, Eiriksdottir G, Lu C, Pellikka N, Wallaschofski H, Kettunen J, Henneman P, Baumert J, Strachan DP, Fuchsberger C, Vitart V, Wilson JF, Pare G, Naitza S, Rudock ME, Surakka I, de Geus EJ, Alizadeh BZ, Guralnik J, Shuldiner A, Tanaka T, Zee RY, Schnabel RB, Nambi V, Kavousi M, Ripatti S, Nauck M, Smith NL, Smith AV, Sundvall J, Scheet P, Liu Y, Ruokonen A, Rose LM, Larson MG, Hoogeveen RC, Freimer NB, Teumer A, Tracy RP, Launer LJ, Buring JE, Yamamoto JF, Folsom AR, Sijbrands EJ, Pankow J, Elliott P, Keaney JF, Sun W, Sarin AP, Fontes JD, Badola S, Astor BC, Hofman A, Pouta A, Werdan K, Greiser KH, Kuss O, Meyer zu Schwabedissen HE, Thiery J, Jamshidi Y, Nolte IM, Soranzo N, Spector TD, Volzke H, Parker AN, Aspelund T, Bates D, Young L, Tsui K, Siscovick DS, Guo X, Rotter JJ, Uda M, Schlessinger D, Rudan I, Hicks AA, Penninx BW, Thorand B, Gieger C, Coresh J, Willemssen G, Harris TB, Uitterlinden AG, Jarvelin MR, Rice K, Radke D, Salomaa V, Willems van Dijk K, Boerwinkle E, Vasani RS, Ferrucci L, Gibson QD, Bandinelli S, Snieder H, Boomsma DI, Xiao X, Campbell H, Hayward C, Pramstaller PP, van Duijn CM, Peltonen L, Psaty BM, Gudnason V, Ridker PM, Homuth G, Koenig W, Ballantyne CM, Witteman JC, Benjamin EJ, Perola M, Chasman DI. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. *Circulation* 2011;**123**:731–738.
 44. Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, Zhu D, Koya JB, Wei L, Li J, Chen ZS. Microbiota in health and diseases. *Signal Transduct Target Ther* 2022;**7**:135.
 45. Heston MB, Hanslik KL, Zarbock KR, Harding SJ, Davenport-Sis NJ, Kerby RL, Chin N, Sun Y, Hoelt A, Deming Y, Vogt NM, Betthausen TJ, Johnson SC, Asthana S, Kollmorgen G, Suridjan I, Wild N, Zetterberg H, Blennow K, Rey FE, Bendlin BB, Ulland TK. Gut inflammation associated with age and Alzheimer's disease pathology: a human cohort study. *Sci Rep* 2023;**13**:18924.
 46. Kavanagh K, Hsu FC, Davis AT, Kritchevsky SB, Rejeski WJ, Kim S. Biomarkers of leaky gut are related to inflammation and reduced physical function in older adults with cardiometabolic disease and mobility limitations. *Geroscience* 2019;**41**:923–933.
 47. Barth E, Srivastava A, Stojilkovic M, Frahm C, Axer H, Witte OW, Marz M. Conserved aging-related signatures of senescence and inflammation in different tissues and species. *Aging (Albany NY)* 2019;**11**:8556–8572.
 48. Soto-Herederero G, Gomez de Las Heras MM, Escrig-Larena JJ, Mittelbrunn M. Extremely differentiated T cell subsets contribute to tissue deterioration during aging. *Annu Rev Immunol* 2023;**41**:181–205.
 49. Mittelbrunn M, Kroemer G. Hallmarks of T cell aging. *Nat Immunol* 2021;**22**:687–698.
 50. Mogilenko DA, Shpynov O, Andhey PS, Arthur L, Swain A, Esaalova E, Brioschi S, Shchukina I, Kerndl M, Bambouskova M, Yao Z, Laha A, Zaitsev K, Burdess S, Gillfilan S, Stewart SA, Colonna M, Artyomov MN. Comprehensive profiling of an aging immune system reveals clonal GZMK(+) CD8(+) T cells as conserved hallmark of inflammaging. *Immunity* 2021;**54**:99–115.e112.
 51. Jin J, Mu Y, Zhang H, Sturmlechner I, Wang C, Jadhav RR, Xia Q, Weyand CM, Goronzy JJ. CISH impairs lysosomal function in activated T cells resulting in mitochondrial DNA release and inflammaging. *Nat Aging* 2023;**3**:600–616.
 52. Wu H, Zhao X, Hochrein SM, Eckstein M, Gubert GF, Knopper K, Mansilla AM, Oner A, Doucet-Ladeveze R, Schmitz W, Ghesquiere B, Theurich S, Dudek J, Gasteiger G, Zerneck A, Kobold S, Kastenmuller W, Vaeth M. Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1 α -mediated glycolytic reprogramming. *Nat Commun* 2023;**14**:6858.
 53. Kim DE, Dolle MET, Vermeij WP, Gyenies A, Vogel K, Hoesjmakers JHJ, Wiley CD, Davalos AR, Hasty P, Desprez PY, Campisi J. Deficiency in the DNA repair protein ERCC1 triggers a link between senescence and apoptosis in human fibroblasts and mouse skin. *Aging Cell* 2020;**19**:e13072.
 54. Coder BD, Wang H, Ruan L, Su DM. Thymic involution perturbs negative selection leading to autoreactive T cells that induce chronic inflammation. *J Immunol* 2015;**194**:5825–5837.
 55. Cunha LL, Perazzo SF, Azzi J, Cravedi P, Riella LV. Remodeling of the immune response with aging: immunosenescence and its potential impact on COVID-19 immune response. *Front Immunol* 2020;**11**:1748.
 56. Ruggiero AD, Vemuri R, Blawas M, Long M, DeStephanis D, Williams AG, Chen H, Justice JN, Macauley SL, Day SM, Kavanagh K. Long-term dasatinib plus quercetin effects on aging outcomes and inflammation in nonhuman primates: implications for senolytic clinical trial design. *Geroscience* 2023;**45**:2785–2803.
 57. Iske J, Seyda M, Heinbokel T, Maenoso R, Minami K, Nian Y, Quante M, Falk CS, Azuma H, Martin F, Passos JF, Niemann CU, Tchonia T, Kirkland JL, Elkhali A, Tullius SG. Senolytics prevent mt-DNA-induced inflammation and promote the survival of aged organs following transplantation. *Nat Commun* 2020;**11**:4289.
 58. Bharath LP, Agrawal M, McCambridge G, Nicholas DA, Hasturk H, Liu J, Jiang K, Liu R, Guo Z, Deeney J, Apovian CM, Snyder-Cappione J, Hawk GS, Fleeman RM, Pihl RMF, Thompson K, Belkina AC, Cui L, Proctor EA, Kern PA, Nikolajczyk BS. Metformin enhances autophagy and normalizes mitochondrial function to alleviate aging-associated inflammation. *Cell Metab* 2020;**32**:44–55.e46.
 59. Rena G, Lang CC. Repurposing metformin for cardiovascular disease. *Circulation* 2018;**137**:422–424.
 60. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, Frezza C, Bernard NJ, Kelly B, Foley NH, Zheng L, Gardet A, Tong Z, Jany SS, Corr SC, Haneklaus M, Caffrey BE, Pierce K, Walmsley S, Beasley FC, Cummins E, Nizet V, Whyte M, Taylor CT, Lin H, Masters SL, Gottlieb E, Kelly VP, Clish C, Auron PE, Xavier RJ, O'Neill LA. Succinate is an inflammatory signal that induces IL-1 β through HIF-1 α . *Nature* 2013;**496**:238–242.
 61. Salazar AM, Aparicio R, Clark RI, Rera M, Walker DW. Intestinal barrier dysfunction: an evolutionarily conserved hallmark of aging. *Dis Model Mech* 2023;**16**:dmm049969.
 62. Martins RR, McCracken AW, Simons MJP, Henriques CM, Rera M. How to catch a smurf?—aging and beyond... In vivo assessment of intestinal permeability in multiple model organisms. *Bio Protoc* 2018;**8**:e2722.
 63. Rera M, Clark RI, Walker DW. Intestinal barrier dysfunction links metabolic and inflammatory markers of aging to death in *Drosophila*. *Proc Natl Acad Sci U S A* 2012;**109**:21528–21533.
 64. Rera M, Bahadorani S, Cho J, Koehler CL, Ulgherait M, Hur JH, Ansari WS, Lo T, Jr., Jones DL, Walker DW. Modulation of longevity and tissue homeostasis by the *Drosophila* PGC-1 homolog. *Cell Metab* 2011;**14**:623–634.
 65. Covino M, Gallo A, Macerola N, Pero E, Ibbaf F, Camilli S, Riccardi L, Sarlo F, De Nino G, Baroni S, Landi F, Montalto M. Role of intestinal inflammation and permeability in patients with acute heart failure. *Medicina (Kaunas)* 2023;**60**:8.
 66. Sliz E, Kalaoja M, Ahola-Olli A, Raitakari O, Perola M, Salomaa V, Lehtimäki T, Karhu T, Viinamäki H, Salmi M, Santalahti K, Jalkanen S, Jokelainen J, Keinänen-Kiukaanniemi S, Mannikko M, Herzog KH, Jarvelin MR, Sebert S, Kettunen J. Genome-wide association study identifies seven novel loci associating with circulating cytokines and cell adhesion molecules in Finns. *J Med Genet* 2019;**56**:607–616.
 67. Olivieri F, Praticchizzo F, Giuliani A, Maccacchione G, Rippo MR, Sabbatinelli J, Bonafe M. miR-21 and miR-146a: the microRNAs of inflammaging and age-related diseases. *Ageing Res Rev* 2021;**70**:101374.
 68. Morris SR, Chen B, Mudd JC, Panigrahi S, Shive CL, Sieg SF, Cameron CM, Zidar DA, Funderburg NT, Younes SA, Rodriguez B, Gianella S, Lederman MM, Freeman ML. Inflammescent CX3CR1+CD57+CD8+ T cells are generated and expanded by IL-15. *JCI Insight* 2020;**5**:e132963.
 69. Andreassen M, Frystyk J, Faber J, Kristensen LO. GH activity and markers of inflammation: a crossover study in healthy volunteers treated with GH and a GH receptor antagonist. *Eur J Endocrinol* 2012;**166**:811–819.
 70. Ortega-Molina A, Lebrero-Fernandez C, Sanz A, Calvo-Rubio M, Deleyto-Seldas N, de Prado-Rivas L, Plata-Gomez AB, Fernandez-Florado E, Gonzalez-Garcia P, Vivas-Garcia Y, Sanchez Garcia E, Grana-Castro O, Price NL, Aroca-Crevillen A, Caleiras E, Monleon D, Borrás C, Casanova-Acebes M, de Cabo R, Efeyan A. A mild increase in nutrient signaling to mTORC1 in mice leads to parenchymal damage, myeloid inflammation and shortened lifespan. *Nat Aging* 2024;**4**:1102–1120.
 71. Forsyth KS, Jiwrajka N, Lovell CD, Toothacre NE, Anguera MC. The coneXion between sex and immune responses. *Nat Rev Immunol* 2024;**24**:487–502.
 72. Olivieri F, Marchegiani F, Maccacchione G, Giuliani A, Raminì D, Fazioli F, Sabbatinelli J, Bonafe M. Sex/gender-related differences in inflammaging. *Mech Ageing Dev* 2023;**211**:111792.
 73. Jaillon S, Berthenet K, Garlanda C. Sexual dimorphism in innate immunity. *Clin Rev Allergy Immunol* 2019;**56**:308–321.
 74. Hagg S, Jylhava J. Sex differences in biological aging with a focus on human studies. *Elife* 2021;**10**:e63425.
 75. Shafeghat M, Kazemian S, Aminorroaya A, Aryan Z, Rezaei N. Toll-like receptor 7 regulates cardiovascular diseases. *Int Immunopharmacol* 2022;**113**:109390.
 76. McClellan M, Brown N, Califf RM, Warner JJ. Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association. *Circulation* 2019;**139**:e44–e54.
 77. Abdellatif M, Rainer PP, Sedej S, Kroemer G. Hallmarks of cardiovascular ageing. *Nat Rev Cardiol* 2023;**20**:754–777.
 78. Wang JC, Bennett M. Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. *Circ Res* 2012;**111**:245–259.
 79. Ramirez CM, Zhang X, Bandyopadhyay C, Rotllan N, Sugiyama MG, Aryal B, Liu X, He S, Kraehling JR, Ulrich V, Lin CS, Velazquez H, Lasuncion MA, Li G, Suarez Y, Tellides G, Swirski FK, Lee WL, Schwartz MA, Sessa WC, Fernandez-Hernando C. Caveolin-1 regulates atherogenesis by attenuating low-density lipoprotein transcytosis and vascular inflammation independently of endothelial nitric oxide synthase activation. *Circulation* 2019;**140**:225–239.
 80. Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, Tokgozoglu L, Lewis EF. Atherosclerosis. *Nat Rev Dis Primers* 2019;**5**:56.
 81. Zhang X, Ramirez CM, Aryal B, Madrigal-Matute J, Liu X, Diaz A, Torrecilla-Parra M, Suarez Y, Cuervo AM, Sessa WC, Fernandez-Hernando C. Cav-1 (caveolin-1) deficiency increases autophagy in the endothelium and attenuates vascular inflammation and atherosclerosis. *Arterioscler Thromb Vasc Biol* 2020;**40**:1510–1522.
 82. Corriere T, Di Marca S, Cataudella E, Pulvirenti A, Alaimo S, Stancanelli B, Malatino L. Neutrophil-to-lymphocyte ratio is a strong predictor of atherosclerotic carotid plaques in older adults. *Nutr Metab Cardiovasc Dis* 2018;**28**:23–27.
 83. Noz MP, Bekkering S, Groh L, Nielsen TM, Lamfers EJ, Schlitzer A, El Messaoudi S, van Royen N, Huys EH, Preijers FW, Smeets EM, Aarntzen EH, Zhang B, Li Y, Bremmers ME, van der Velden WJ, Dolstra H, Joosten LA, Gomes ME, Netea MG, Riksen NP. Reprogramming of bone marrow myeloid progenitor cells in patients with severe coronary artery disease. *Elife* 2020;**9**:e60939.

84. Tyrrell DJ, Wrapp KM, Chen J, Wang H, Song J, Blin MG, Bolding C, Vardaman D, 3rd, Giles K, Tidwell H, Ali MA, Janappareddi A, Wood SC, Goldstein DR. Clonally expanded memory CD8(+) T cells accumulate in atherosclerotic plaques and are pro-atherogenic in aged mice. *Nat Aging* 2023;**3**:1576–1590.
85. Tyrrell DJ, Goldstein DR. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6. *Nat Rev Cardiol* 2021;**18**:58–68.
86. Alcaraz MJ, Alcaraz A, Teruel-Montoya R, Campillo JA, de la Torre A, Munoz A, Tomas C, Puche G, Baguena C, Cano A, Minguela A, Bernal E. Subclinical atherosclerosis and immune activation in young HIV-infected patients with telomere shortening. *Aging (Albany NY)* 2021;**13**:18094–18105.
87. Nam KW, Kwon HM, Jeong HY, Park JH, Kim SH, Jeong SM. High neutrophil to lymphocyte ratios predict intracranial atherosclerosis in a healthy population. *Atherosclerosis* 2018;**269**:117–121.
88. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. *N Engl J Med* 1997;**336**:973–979.
89. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M. Inflammatory markers and onset of cardiovascular events: results from the health ABC study. *Circulation* 2003;**108**:2317–2322.
90. Libby P. Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. *J Am Coll Cardiol* 2017;**70**:2278–2289.
91. Bruunsgaard H, Skinhoj P, Pedersen AN, Schroll M, Pedersen BK. Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. *Clin Exp Immunol* 2000;**121**:255–260.
92. Zhang L, Connelly JJ, Peppel K, Brian L, Shah SH, Nelson S, Crosslin DR, Wang T, Allen A, Kraus WE, Gregory SG, Hauser ER, Freedman NJ. Aging-related atherosclerosis is exacerbated by arterial expression of tumor necrosis factor receptor-1: evidence from mouse models and human association studies. *Hum Mol Genet* 2010;**19**:2754–2766.
93. Zeng Y, Nie C, Min J, Liu X, Li M, Chen H, Xu H, Wang M, Ni T, Li Y, Yan H, Zhang JP, Song C, Chi LQ, Wang HM, Dong J, Zheng GY, Lin L, Qian F, Qi Y, Liu X, Cao H, Wang Y, Zhang L, Li Z, Zhou Y, Wang Y, Lu J, Li J, Qi M, Bolund L, Yashin A, Land KC, Gregory S, Yang Z, Gottschalk W, Tao W, Wang J, Wang J, Xu X, Bae H, Nygaard M, Christiansen L, Christensen K, Franceschi C, Lutz MW, Gu J, Tan Q, Peris T, Sebastiani P, Deelen J, Slagboom E, Hauser E, Xu H, Tian XL, Yang H, Vaupel JVV. Novel loci and pathways significantly associated with longevity. *Sci Rep* 2016;**6**:21243.
94. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chiquiere-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Pina IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tzotsi H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med* 2021;**385**:1451–1461.
95. Liberale L, Badimon L, Montecucco F, Luscher TF, Libby P, Camici GG. Inflammation, aging, and cardiovascular disease: JACC review topic of the week. *J Am Coll Cardiol* 2022;**79**:837–847.
96. Varadhan R, Yao W, Matteini A, Beamer BA, Xue QL, Yang H, Manwani B, Reiner A, Jenny N, Parekh N, Fallin MD, Newman A, Bandeen-Roche K, Tracy R, Ferrucci L, Walston J. Simple biologically informed inflammatory index of two serum cytokines predicts 10 year all-cause mortality in older adults. *J Gerontol A Biol Sci Med Sci* 2014;**69**:165–173.
97. Theriault S, Dina C, Messika-Zeitoun D, Le Scouarnec S, Capoulade R, Gaudreault N, Rigade S, Li Z, Simonet F, Lamontagne M, Clavel MA, Arsenault BJ, Boreau AS, Lecointe S, Baron E, Bonnaud S, Karakachoff M, Charpentier E, Fellah I, Roussel JC, Philippe Verhoye J, Baufretton C, Probst V, Roussel R; D.E.S.I.R. Study Group, Redon R, Dagenais F, Pibarot P, Mathieu P, Le Tourneau T, Bosse Y, Schott JJ. Genetic association analyses highlight IL6, ALPL, and NAV1 as 3 new susceptibility genes underlying calcific aortic valve stenosis. *Circ Genom Precis Med* 2019;**12**:e002617.
98. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JE, Shah T, Sofat R, Guo Y, Chung C, Peasey A, Pfister R, Mooijaart SP, Ireland HA, Leusink M, Langenberg C, Li KW, Palmen J, Howard P, Cooper JA, Drenos F, Hardy J, Nalls MA, Li YR, Lowe G, Stewart M, Bielinski SJ, Peto J, Timpson NJ, Gallacher J, Dunlop M, Houlston R, Tomlinson I, Tzoulaki I, Luan J, Boer JM, Forouhi NG, Omland-Moret NC, van der Schouw YT, Schnabel RB, Hubacek JA, Kubinova R, Bacevicene M, Tamosiunas A, Pajak A, Topor-Madry R, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, de Faire U, Ferrucci L, Bandenelli S, Tanaka T, Meschia JF, Singleton A, Navis G, Mateo Leach I, Bakker SJ, Gansevoort RT, Ford I, Epstein SE, Burnett MS, Devaney JM, Jukema JW, Westendorp RG, Jan de Borst G, van der Graaf Y, de Jong PA, Mailand-van der Zee AH, Klungel OH, de Boer A, Doevevands PA, Stephens JW, Eaton CB, Robinson JG, Manson JE, Fowkes FG, Frayling TM, Price JF, Whincup PH, Morris RW, Lawlor DA, Smith GD, Ben-Shlomo Y, Redline S, Lange LA, Kumari M, Wareham NJ, Verschuren WM, Benjamin EJ, Whittaker JC, Hamsten A, Dudbridge F, Delaney JA, Wong A, Kuh D, Hardy R, Castillo BA, Connolly JJ, van der Harst P, Brunner EJ, Marmot MG, Wassel CL, Humphries SE, Talmud PJ, Kivimaki M, Asselbergs FW, Voevoda M, Bobak M, Pikhart H, Wilson JG, Hakonarson H, Reiner AP, Keating BJ, Sattar N, Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. *Lancet* 2012;**379**:1214–1224.
99. McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, Codding CE, Carlson TH, Delles C, Lee JS, Sattar N. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. *Ann Rheum Dis* 2015;**74**:694–702.
100. Van Tassell BW, Buckley LF, Carbone S, Trankle CR, Canada JM, Dixon DL, Abouzaki N, Oddi-Erdle C, Biondi-Zoccai G, Arena R, Abbate A. Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2). *Clin Cardiol* 2017;**40**:626–632.
101. Van Tassell BW, Trankle CR, Canada JM, Carbone S, Buckley L, Kadariya D, Del Buono MG, Billingsley H, Wohlford G, Viscusi M, Oddi-Erdle C, Abouzaki NA, Dixon D, Biondi-Zoccai G, Arena R, Abbate A. IL-1 blockade in patients with heart failure with preserved ejection fraction. *Circ Heart Fail* 2018;**11**:e005036.
102. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, Group CT. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med* 2017;**377**:1119–1131.
103. Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Ilturriaga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S, Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ, Investigators C. Low-dose methotrexate for the prevention of atherosclerotic events. *N Engl J Med* 2019;**380**:752–762.
104. Roubille F, Kritikou E, Busseuil D, Barrere-Lemaire S, Tardif JC. Colchicine: an old wine in a new bottle? *Antiinflamm Antiallergy Agents Med Chem* 2013;**12**:14–23.
105. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, Lopez-Sendon J, Ostadal P, Koenig W, Angoulvant D, Gregoire JC, Lavoie MA, Dube MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L'Allier PL, Guertin MC, Roubille F. Efficacy and safety of low-dose colchicine after myocardial infarction. *N Engl J Med* 2019;**381**:2497–2505.
106. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozlu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J* 2021;**42**:3227–3337.
107. Ruccia A, Macri F, Castiglione S, Badi I, Vinci MC, Zuccolo E. MicroRNA-34a: the bad guy in age-related vascular diseases. *Cell Mol Life Sci* 2021;**78**:7355–7378.
108. Sun X, Feinberg MW. Vascular endothelial senescence: pathobiological insights, emerging long noncoding RNA targets, challenges and therapeutic opportunities. *Front Physiol* 2021;**12**:693067.
109. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu XF, Ireland MA, Lenderink T, Latchem D, Hoogslag P, Jerzewski A, Nierop P, Whelan A, Hendriks R, Swart H, Schaap J, Kuijper AFM, van Hesse MWJ, Saklani P, Tan I, Thompson AG, Morton A, Judkins C, Bax WA, Dirksen M, Alings M, Hankey GJ, Budgeon CA, Tijssen JGP, Cornel JH, Thompson PL; LoDoCo2 trial I. Colchicine in patients with chronic coronary disease. *N Engl J Med* 2020;**383**:1838–1847.
110. Wintrich J, Kindermann I, Ukena C, Selejan S, Werner C, Maack C, Laufs U, Tschöpe C, Anker SD, Lam CSP, Voors AA, Bohm M. Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. *Clin Res Cardiol* 2020;**109**:1079–1098.
111. Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, Brennan DM, Koenig W, Jukema JW, Nambi V, Wright RS, Menon V, Lincoff AM, Nissen SE, Investigators V. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. *JAMA* 2014;**311**:252–262.
112. Kosiborod MN, Verma S, Borlaug BA, Butler J, Davies MJ, Jon Jensen T, Rasmussen S, Erlang Marstrand P, Petrie MC, Shah SJ, Ito H, Schou M, Melenovsky V, Abhayaratna VV, Kitzman DW; STEP-HFpEF Trial Committees and Investigators. Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial. *Circulation* 2024;**149**:204–216.
113. Ferraz-Amaro I, Hernandez-Hernandez MV, Tejera-Segura B, Delgado-Frias E, Macia-Diaz M, Machado JD, Diaz-Gonzalez F. Effect of IL-6 receptor blockade on proprotein convertase subtilisin/kexin type-9 and cholesterol efflux capacity in rheumatoid arthritis patients. *Horm Metab Res* 2019;**51**:200–209.
114. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA, Jr. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. *J Exp Med* 1984;**160**:618–623.
115. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A, Weyand CM. Inflammation, immunity, and hypertension. *Hypertension* 2011;**57**:132–140.
116. Liberale L, Dallegri F, Montecucco F, Carbone F. Pathophysiological relevance of macrophage subsets in atherogenesis. *Thromb Haemost* 2017;**117**:7–18.
117. Glass CK, Witztum JL. Atherosclerosis. The road ahead. *Cell* 2001;**104**:503–516.
118. De Ciuceci C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of

- angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. *Arterioscler Thromb Vasc Biol* 2005;**25**:2106–2113.
119. Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. *Nat Rev Immunol* 2019;**19**:477–489.
 120. Baziotti V, La Rose AM, Maassen S, Bianchi F, de Boer R, Halmos B, Dabral D, Guilbaud E, Flohr-Svendsen A, Groenen AG, Marmolejo-Garza A, Koster MH, Kloosterhuis NJ, Havinga R, Pranger AT, Langelaar-Makkinje M, de Bruin A, van de Sluis B, Kohan AB, Yvan-Charvet L, van den Bogaart G, Westertep M. T cell cholesterol efflux suppresses apoptosis and senescence and increases atherosclerosis in middle aged mice. *Nat Commun* 2022;**13**:3799.
 121. Hornburg D, Wu S, Moqri M, Zhou X, Contrepois K, Bararpour N, Traber GM, Su B, Metwally AA, Avina M, Zhou W, Ubellacker JM, Mishra T, Schussler-Fiorenza Rose SM, Kavathas PB, Williams KJ, Snyder MP. Dynamic lipidome alterations associated with human health, disease and ageing. *Nat Metab* 2023;**5**:1578–1594.
 122. Kromhout D, Yasuda S, Geleijnse JM, Shimokawa H. Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work? *Eur Heart J* 2012;**33**:436–443.
 123. Thorp EB. Proresolving lipid mediators restore balance to the vulnerable plaque. *Circ Res* 2016;**119**:972–974.
 124. Ramirez CM, Torrecilla-Parra M, Pardo-Marques V, de-Frutos MF, Perez-Garcia A, Tabraue C, de la Rosa JV, Martin-Rodriguez P, Diaz-Sarmiento M, Nunez U, Orizaola MC, Traves PG, Camps M, Bosca L, Castrillo A. Crosstalk between LXR and caveolin-1 signaling supports cholesterol efflux and anti-inflammatory pathways in macrophages. *Front Endocrinol (Lausanne)* 2021;**12**:635923.
 125. Le Master E, Paul A, Lazarko D, Aguilar V, Ahn SJ, Lee JC, Minshall RD, Levitan I. Caveolin-1 is a primary determinant of endothelial stiffening associated with dyslipidemia, disturbed flow, and ageing. *Sci Rep* 2022;**12**:17822.
 126. Caravia XM, Lopez-Oficin C. Regulatory roles of miRNAs in aging. *Adv Exp Med Biol* 2015;**887**:213–230.
 127. Ramirez CM, Goedeke L, Fernandez-Hernando C. “Micromanaging” metabolic syndrome. *Cell Cycle* 2011;**10**:3249–3252.
 128. Aranda JF, Madrigal-Matute J, Rotllan N, Fernandez-Hernando C. MicroRNA modulation of lipid metabolism and oxidative stress in cardiometabolic diseases. *Free Radic Biol Med* 2013;**64**:31–39.
 129. Perez-Garcia A, Torrecilla-Parra M, Fernandez-de Frutos M, Martin-Martin Y, Pardo-Marques V, Ramirez CM. Posttranscriptional regulation of insulin resistance: implications for metabolic diseases. *Biomolecules* 2022;**12**:208.
 130. Olivieri F, Rippon MR, Monsurro V, Salvioli S, Capri M, Procopio AD, Franceschi C. MicroRNAs linking inflamm-aging, cellular senescence and cancer. *Ageing Res Rev* 2013;**12**:1056–1068.
 131. Wagner V, Kern F, Hahn O, Schaum N, Ludwig N, Fehlmann T, Engel A, Henn D, Rishik S, Isakova A, Tan M, Sit R, Neff N, Hart M, Meese E, Quake S, Wyss-Coray T, Keller A. Characterizing expression changes in noncoding RNAs during aging and heterochronic parabiosis across mouse tissues. *Nat Biotechnol* 2024;**42**:109–118.
 132. Lai CY, Wu YT, Yu SL, Yu YH, Lee SY, Liu CM, Hsieh WS, Hwu HG, Chen PC, Jeng SF, Chen WJ. Modulated expression of human peripheral blood microRNAs from infancy to adulthood and its role in aging. *Ageing Cell* 2014;**13**:679–689.
 133. Fehlmann T, Lehallier B, Schaum N, Hahn O, Kahraman M, Li Y, Grammes N, Geffers L, Backes C, Balling R, Kern F, Kruger R, Lammert F, Ludwig N, Meder B, Fromm B, Maetzler W, Berg D, Brockmann K, Deuschle C, von Thaler AK, Eschweiler GV, Milman S, Barzilai N, Reichert M, Wyss-Coray T, Meese E, Keller A. Common diseases alter the physiological age-related blood microRNA profile. *Nat Commun* 2020;**11**:5958.
 134. Ajoalabady A, Pratico D, Vinciguerra M, Lip GYH, Franceschi C, Ren J. Inflammaging: mechanisms and role in the cardiac and vasculature. *Trends Endocrinol Metab* 2023;**34**:373–387.
 135. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. *Nat Rev Cardiol* 2017;**14**:591–602.
 136. Kessler EL, Oerlemans M, van den Hoogen P, Yap C, Sluijter JPG, de Jager SCA. Immunomodulation in heart failure with preserved ejection fraction: current state and future perspectives. *J Cardiovasc Transl Res* 2021;**14**:63–74.
 137. Wohlfahrt P, Redfield MM, Melenovsky V, Lopez-Jimenez F, Rodeheffer RJ, Borlaug BA. Impact of chronic changes in arterial compliance and resistance on left ventricular ageing in humans. *Eur J Heart Fail* 2015;**17**:27–34.
 138. Mesquita T, Lin YN, Ibrahim A. Chronic low-grade inflammation in heart failure with preserved ejection fraction. *Ageing Cell* 2021;**20**:e13453.
 139. Pugliese NR, Pellicori P, Filidei F, De Biase N, Maffia P, Guzik TJ, Masi S, Taddei S, Cleland JGF. Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions. *Cardiovasc Res* 2023;**118**:3536–3555.
 140. Matyas C, Trojnar E, Zhao S, Arif M, Mukhopadhyay P, Kovacs A, Fabian A, Tokodi M, Bagyura Z, Merkely B, Kohidai L, Lajko E, Takacs A, He Y, Gao B, Paloczi J, Lohoff FW, Hasko G, Ding WX, Pacher P. PCSK9, a promising novel target for age-related cardiovascular dysfunction. *JACC Basic Transl Sci* 2023;**8**:1334–1353.
 141. Sansoni P, Vescovin R, Fagnoni FF, Akbar A, Arens R, Chiu YL, Cicin-Sain L, Dechanet-Merville J, Derhovanessian E, Ferrando-Martinez S, Franceschi C, Frasca D, Fulop T, Furman D, Gkrania-Klotsas E, Goodrum F, Grubeck-Loebenstein B, Hurme M, Kern F, Lilleri D, Lopez-Botet M, Maier AB, Marandu T, Marchant A, Mathei C, Moss P, Muntassell A, Remmerswaal EB, Riddell NE, Rothe K, Sauce D, Shin EC, Simanek AM, Smithey MJ, Soderberg-Nauder C, Solana R, Thomas PG, van Lier R, Pawelec G, Nikolich-Zugich J. New advances in CMV and immunosenescence. *Exp Gerontol* 2014;**55**:54–62.
 142. Ranjbarvaziri S, Zeng A, Wu I, Greer-Short A, Farshidfar F, Budan A, Xu E, Shenwai R, Kozubov M, Li C, Van Pell M, Grafton F, MacKay CE, Song X, Priest JR, Argast G, Mandegar MA, Hoey T, Yang J. Targeting HDAC6 to treat heart failure with preserved ejection fraction in mice. *Nat Commun* 2024;**15**:1352.
 143. Shah SJ, Borlaug BA, Kitzman DW, McCulloch AD, Blaxall BC, Agarwal R, Chirinos JA, Collins S, Deo RC, Gladwin MT, Granzier H, Hummel SL, Kass DA, Redfield MM, Sam F, Wang TJ, Desvigne-Nickens P, Adhikari BB. Research priorities for heart failure with preserved ejection fraction: National Heart, Lung, and Blood Institute Working Group Summary. *Circulation* 2020;**141**:1001–1026.
 144. Broch K, Anstensrud AK, Woxholt S, Sharma K, Tollefsen IM, Bendz B, Aakhus S, Ueland T, Amundsen BH, Damas JK, Berg ES, Bjorkelund E, Bendz C, Hopp E, Kleivland O, Stensath KH, Opdahl A, Klow NE, Seljeflot I, Andersen GO, Wiseth R, Aukrust P, Gullestad L. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. *J Am Coll Cardiol* 2021;**77**:1845–1855.
 145. Liberale L, Bonetti NR, Puspitasari YM, Vukolic A, Akhmedov A, Diaz-Canestro C, Keller S, Montecucco F, Merlini M, Semerano A, Giacalone G, Bacigaluppi M, Sessa M, Ruschitzka F, Luscher TF, Libby P, Beer JH, Camici GG. TNF-alpha antagonism rescues the effect of ageing on stroke: perspectives for targeting inflamm-aging. *Eur J Clin Invest* 2021;**51**:e13600.
 146. Trial J, Diaz Lankenau R, Angelini A, Tovar Perez JE, Taffet GE, Entman ML, Cieslik KA. Treatment with a DC-SIGN ligand reduces macrophage polarization and diastolic dysfunction in the aging female but not male mouse hearts. *Geroscience* 2021;**43**:881–899.
 147. Shen S, Duan J, Hu J, Qi Y, Kang L, Wang K, Chen J, Wu X, Xu B, Gu R. Colchicine alleviates inflammation and improves diastolic dysfunction in heart failure rats with preserved ejection fraction. *Eur J Pharmacol* 2022;**929**:175126.
 148. Campbell P, Rutten FH, Lee MM, Hawkins NM, Petrie MC. Heart failure with preserved ejection fraction: everything the clinician needs to know. *Lancet* 2024;**403**:1083–1092.
 149. Pan JA, Lin H, Wang CQ, Zhang JF, Gu J. Association between long-term prescription of fexofenadine and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia. *Heart Vessels* 2020;**35**:1446–1453.
 150. Tanaka Y, Nagoshi T, Takahashi H, Oi Y, Yasutake R, Yoshii A, Kimura H, Kashiwagi Y, Tanaka TD, Shimoda M, Yoshimura M. URAT1 is expressed in cardiomyocytes and dotorund attenuates the development of diet-induced metabolic heart disease. *iScience* 2023;**26**:107730.
 151. Mone P, Lombardi A, Gambardella J, Pansini A, Macina G, Morgante M, Frullone S, Santulli G. Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and heart failure with preserved ejection fraction. *Diabetes Care* 2022;**45**:1247–1251.
 152. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozd J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katoka T, Kitakaze M, Merkely B, O'Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderang U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. *N Engl J Med* 2022;**387**:1089–1098.
 153. Borlaug BA, Kitzman DW, Davies MJ, Rasmussen S, Barros E, Butler J, Einfeldt MN, Hovingh GK, Moller DV, Petrie MC, Shah SJ, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Nunez J, Perna E, Schou M, Senni M, van der Meer P, Von Lewinski D, Wolf D, Kosiborod MN. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. *Nat Med* 2023;**29**:2358–2365.
 154. Shi YJ, Yang CG, Qiao WB, Liu YC, Liu SY, Dong GJ. Sacubitril/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction. *Eur J Pharmacol* 2023;**961**:176170.
 155. Wilck N, Marko L, Balogh A, Kraker K, Herse F, Bartolomeaus H, Szijarto IA, Gollasch M, Reichhart N, Strauss O, Heuser A, Brockschneider D, Kretschmer A, Lesche R, Sohler F, Stasch JP, Sandner P, Luft FC, Muller DN, Dechend R, Haase N. Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction. *JCI Insight* 2018;**3**:e96006.
 156. Deng Y, Xie M, Li Q, Xu X, Ou W, Zhang Y, Xiao H, Yu H, Zheng Y, Liang Y, Jiang C, Chen G, Du D, Zheng W, Wang S, Gong M, Chen Y, Tian R, Li T. Targeting mitochondria-inflammation circuit by beta-hydroxybutyrate mitigates HFpEF. *Circ Res* 2021;**128**:232–245.
 157. Yang K, Hou R, Zhao J, Wang X, Wei J, Pan X, Zhu X. Lifestyle effects on aging and CVD: a spotlight on the nutrient-sensing network. *Ageing Res Rev* 2023;**92**:102121.
 158. Full KM, Huang T, Shah NA, Allison MA, Michos ED, Duprez DA, Redline S, Lutsey PL. Sleep irregularity and subclinical markers of cardiovascular disease: the multi-ethnic study of atherosclerosis. *J Am Heart Assoc* 2023;**12**:e027361.
 159. Zhang P, Catterson JH, Gronke S, Partridge L. Inhibition of S6K lowers age-related inflammation and increases lifespan through the endolysosomal system. *Nat Aging* 2024;**4**:491–509.

160. Di Giosia P, Stamerra CA, Giorgini P, Jamialahamdi T, Butler AE, Sahebkar A. The role of nutrition in inflammaging. *Ageing Res Rev* 2022;**77**:101596.
161. Rasa SMM, Annunziata F, Krepelova A, Nunna S, Omrani O, Gebert N, Adam L, Kappel S, Hohn S, Donati G, Jurkowski TP, Rudolph KL, Ori A, Neri F. Inflammaging is driven by up-regulation of innate immune receptors and systemic interferon signaling and is ameliorated by dietary restriction. *Cell Rep* 2022;**39**:111017.
162. Goh J, Wong E, Soh J, Maier AB, Kennedy BK. Targeting the molecular & cellular pillars of human aging with exercise. *FEBS J* 2023;**290**:649–668.
163. Palmu J, Watrous JD, Mercader K, Havulinna AS, Lagerborg KA, Salosensaari A, Inouye M, Larson MG, Rong J, Vasani RS, Lahti L, Andres A, Cheng S, Jousilahti P, Salomaa V, Jain M, Niiranen TJ. Eicosanoid inflammatory mediators are robustly associated with blood pressure in the general population. *J Am Heart Assoc* 2020;**9**:e017598.
164. Lau ES, Roshandelpoor A, Zarbafian S, Wang D, Guseh JS, Allen N, Varadarajan V, Nayor M, Shah RV, Lima JAC, Shah SJ, Yu B, Alotaibi M, Cheng S, Jain M, Lewis GD, Ho JE. Eicosanoid and eicosanoid-related inflammatory mediators and exercise intolerance in heart failure with preserved ejection fraction. *Nat Commun* 2023;**14**:7557.
165. Malandish A, Gulati M. The impacts of exercise interventions on inflammaging markers in overweight/obesity patients with heart failure: a systematic review and meta-analysis of randomized controlled trials. *Int J Cardiol Heart Vasc* 2023;**47**:101234.